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Human papillomavirus (HPV) is the single most common sexually transmitted 
infection (STI) in the United States. Each year it is the cause of nearly 4,000 deaths in 
women. In 2006, the first vaccine, Gardasil™, was released into the market for 
females ages 9 to 26, with the CDC targeting girls ages 11 and 12 years old for 
vaccination. This vaccine has created a wave of new state policy initiatives aimed at 
promoting the vaccine, some of which have caused great controversy. Currently, most 
of the literature has focused on intentions of young women, parents, and health 
providers to vaccinate against HPV. Results indicated that several barriers may inhibit 
vaccination, particularly for pre-adolescent girls. This study is one of the first to 
examine actual vaccination behaviors, as well as current barriers and supports 
experienced by health providers. A stratified random sample of health providers was 
selected in four states with varying state policy initiatives. Out of 1490 health 
providers, 227 responded to a survey that asked about their vaccination behaviors and 
their perceived barriers and supports to vaccination. Results indicated that health 
providers are vaccinating older females at significantly higher rates than younger 
teens and pre-adolescents in three of the four states. Additionally, state policy does 
seem to have some relationship with health providers’ HPV vaccination of girls 13-
17. Further, fewer barriers faced by health providers was predictive of increased 
vaccination rates for providers vaccinating girls 9-12 and girls 13-17. Important 
barriers to consider are financial burden and negative perception of parents about 
vaccination, with key supports including personal belief in the positive impact of the 
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vaccine and a personal comfort level talking with parents about the vaccine. While 
there are limitations with the generalizability of this study, there are important 
implications for future researchers, health providers, consumers, and policy makers 
raised by this study. Given social work’s commitment to reducing barriers for 
consumers and improving supports that will foster health promoting behavior, 































Chapter 1: Introduction to the Problem/Needs Statement 
 
Human Papillomavirus as a Social Problem 
Until recently, the burden of Human Papillomavirus (HPV), the single most 
common sexually transmitted infection (STI) in America, has fallen on both society 
and the women and men infected. There are over 6 million new infections of genital 
HPV annually, which is responsible for cervical cancer, genital warts, and anogenital 
cancers (Markowitz, et al., 2007). Additionally, HPV can cause penile cancer and 
recurrent respiratory papillomatosis (RRP) in infants whose mothers are infected with 
HPV (Gudeman, 2007). While 80 percent of individuals will be infected with HPV at 
some point in their lifetime, most infections are asymptomatic or spontaneously 
regress. Nearly 27 percent of girls and women are infected with HPV at any given 
time, with an increase to 45 percent for females aged 14 to 24 (Gostin & DeAngelis, 
2007). With such high rates of infection, it is not surprising that in 2000, genital HPV 
cost the nation $2.9 billion in direct medical costs (Chesson, Blandford, Gift, Tao & 
Irwin, 2004).  
Even more costly are the lives lost: in 2008, it is expected that 3,870 women 
will die in the United States from cervical cancer, many of which will be low-income 
and minority women (Markowitz, et al., 2007). Currently, African-Americans are 1.5 
times more likely to experience an incidence of cervical cancer and two times more 
likely to experience mortality than Caucasian women. Incidence rates for Hispanic 
and some Asian subpopulations are also higher than Caucasian rates. Cervical cancer 
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mortality rates are two to five times higher for Native American women than for 
Caucasian women (Smith, Christopher, & McCormick, 2004). Women of Mexican 
descent receive the least preventative care services within Latina populations 
(Borrayo & Jenkins, 2003). Southeastern immigrants have the lowest levels of Pap 
screenings of all racial/ethnic populations in America (Jackson, et al., 2000). Finally, 
southern states have higher incidence of cervical cancer as well (Markowitz, et al., 
2007). 
The burden, however, may be lifted in the upcoming years, as a new 
technology of healthcare has entered the picture. On June 8th, 2006, the U.S. Food and 
Drug Administration (FDA) approved Gardasil ™ as the first vaccine to protect 
women between the ages of 9 and 26 against HPV (Markowitz, et al., 2007). In 2007, 
the Advisory Council on Immunization Practices (ACIP) recommended that all girls 
aged 11 and 12 be vaccinated against HPV, with the indication that girls can be 
vaccinated as early as 9 years of age, and older females between the ages of 13 and 26 
can receive the vaccine as well.  In the United Kingdom (UK), research has estimated 
the impact for giving the vaccine to a cohort of 12-year-old girls at 100 percent 
coverage would reduce 70 percent of high-grade cervical cancer lesions and result in 
a 76 percent decrease in cervical cancer deaths for that cohort (Adams, Jasani, & 
Fiander, 2007).  
Adolescents are an important service target population for multiple reasons. 
Dempsey, Koutsky, and Golden (2007) indicate that while there are certainly risk 
factors for HPV infection, they assert that HPV is “nearly ubiquitous among sexually 
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active individuals” and that individuals do not need to engage in high risk sexual 
behavior to become infected (p. 506). In the U.S., a third of ninth graders report 
having sexual intercourse and two thirds of students report doing so by the time they 
are seniors in high school (Hopenhayn, Christian, Christian, & Schoenberg, 2007). In 
connection with this, Charo (2007) points out that youth drop out rates from school 
begin to increase at age 13 and those youth are more likely to engage in sexual 
activity earlier than youth who do not leave school. Consequently, the vaccine will be 
most effective prior to sexual debut, which includes namely pre-adolescents and 
young adolescents (Markowitz, et al., 2007).  
Additionally, according to Newacheck, Park, Brindis, Biehl, and Irwin (2004), 
older adolescents (ages 15 to 18) are at significantly higher risk for being 
underinsured than those ages 10 to 14 (13.7% vs. 11.0% respectively). In 2002, 
reportedly 12 percent of the adolescent population was underinsured (Dempsey & 
Davis, 2006). Uninsured adolescents may avoid health care costs and not seek 
vaccination. Additionally, 20 percent of adolescents living in poverty are uninsured. 
Even youth who do have access to preventative healthcare services often do not 
receive guidance or counseling from healthcare providers. Causes of this neglect 
include provider self-efficacy around counseling, concerns that counseling is not 
desired by family members, and perceptions that youth do not belong to a high-risk 




Importance of Health Care Access 
 The prior paragraph introduces the ideas that there are access barriers related 
to health care services. According to Rooks and colleagues (2008), “Access to quality 
health care is associated with better prevention, detection, and control of chronic 
disease processes and consequently improved functional outcomes” (p. 600). 
Typically, access to health care means having a usual source of care and accessibility 
to that source of care through health insurance (Weinick, Zuvekas, & Cohen, 2000). 
In contrast, poor access to care has been discussed as relying on emergency services 
for care, using public or hospital-based clinics, and not using a private physician’s 
office for care.    
The notion of health disparities arose in 1984 when the secretary of the 
Department of Health and Human Services created a Task Force on Black and 
Minority Health (Weinick, Zuvekas, & Cohen, 2000). It came out of awareness that 
minority groups were experiencing increased health problems compared to their 
White counterparts. Not only have such disparities continued for health outcomes for 
racial and ethnic minorities, but also there are disparities in having health insurance as 
well as utilizing health care services. For example, Whites are more likely to have 
private insurance, whereas African Americans are more likely to have Medicaid. 
Additionally, Whites are twice as likely to have health insurance and a routine health 
care provider, as compared with Hispanic individuals. Both access and use of health 
care services are often seen as associated with demographic characteristics of 
individuals, such as race or ethnicity, as well as economic factors, such as sufficient 
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income to purchase health insurance as well as pay for medical care. Weinick, 
Zuvekas, and Cohen, (2000) found that while controlling for health insurance status 
and income level does reduce the disparities in access and use of health care services 
among racial and ethnic minority groups, it does not eliminate the disparities. The 
authors suggest that additional factors related to racial and ethnic differences are at 
work, such as intentional or unintentional discrimination by the provider or linguistic 
challenges by the provider.  
Racial minority groups face structural barriers, which include residential 
segregation in areas with fewer medical facilities, having reduced financial resources 
and limited health insurance, as well as limited knowledge about innovative medical 
treatments (Rooks et al., 2008). Race is often linked to access to society’s high 
quality resources. Bach, Pham, Schrag, Tate and Hargraves (2004) found that African 
American patients are more likely to receive services from physicians without board 
certification in their area of specialty as compared with their White counterparts. In 
connection with that, those physicians treating African American patients reported 
more barriers to obtaining high quality medical resources than those physicians who 
were treating White patients.   
In addition to race and ethnicity, an individual’s socioeconomic status is 
important in that a consequence of lower income status is having less access to health 
care that is affordable. Ross and Mirowsky (2000) have a “health commodity 
hypothesis” which posits that being in better socioeconomic standing provides 
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opportunities to obtain health insurance, which allows individuals to purchase health 
care services with more frequency and choose higher quality services (p. 292).  
When considering cervical cancer incidence and mortality, it was mentioned 
above that there are distinct disparities present for populations from racial and ethnic 
minority backgrounds, as well as lower socioeconomic class. This is further seen in 
the utilization of Pap screenings, in which there have been lower rates of utilization 
for racial and ethnic minorities, as well as those with limited health insurance and 
financial resources (Couglin, Leadbetter, Richards, & Sabatino, 2008). Additional 
factors associated with screening include having a usual health care source and living 
in a location with increased health care providers.  
The literature is consistent in its conclusion that there is a significant 
correlation between access to preventive and acute health care services and income, 
health insurance coverage, and race and ethnicity, such that having less income, less 
health insurance coverage, and having a minority racial background is associated with 
less access to care. Thus, in order to fully understand barriers to accessing cervical 
cancer prevention services in general and vaccinating girls against HPV in particular, 
it is necessary to include indicators such as health insurance status, income level, and 
racial and ethnic background when considering the sample as well as the research 
questions.  
Prevention as a Social Work Intervention 
Although social work once had a healthy marriage with public health, 
particularly around the prevention and treatment of syphilis, there has been a distinct 
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shift away from the public health prevention arena by the profession into clinical 
treatment and intervention since the 1950s (Gochros & Schultz, 1972). This has 
especially been the case for addressing issues relating to human sexuality, particularly 
for young women. Social work has periodically been conflicted as to where and how 
to focus efforts in addressing sexuality issues. As early as 1976, Brashear highlighted 
this conflict well in the following passage: 
A pervasive debate in the field has been the prevention versus the intervention 
stance, with sharp division frequently occurring. Such issues have tended to 
obscure the emergence of a specific area of expertise, such as knowledge of 
human sexuality. This is especially true when that knowledge and its best-
known strategies are most closely identified with an educative focus, as 
opposed to a treatment strategy with which social work has had a major 
identification. (p. 4) 
Despite the challenges, a mandate exists for prevention efforts. In 1987, 
NASW charged that social workers involved in public health efforts focus on 
planning and carrying out programs to prevent ill health, the use of epidemiological 
principles to examine the association between social factors and the prevalence of 
disease, and efforts to increase access to health care services (NASW, 1987). Since 
that time, similar directives have been given to social workers interested in healthcare 
services: to focus efforts on research that will impact policy and program 
development to better serve clients who utilize those service (Cowles, 2000).  
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Much of what primary prevention aims to achieve is congruent with the 
activities of social work research and practice. This can be seen in the five 
“technologies” of primary prevention, which include: 1) education; 2) social change 
in the community or society; 3) promotion of competency; 4) promotion of natural 
caregiving; and 5) consultation and collaboration (Gullotta, 1987). This study 
inquired about technologies #1, #2, #3, and #5. In an effort to meet the most current 
public health needs within the U.S., this study also incorporated two of the goals 
identified by the Centers for Disease Control (CDC) in its recent report entitled, 
“Public Health Research Needs: 2006-2015” (CDC, 2006). In this report, the CDC 
identified goals that aim to reduce health care access inequities and improve the 
quality of life of all individuals.  
First, the CDC goal of Healthy People in Every Stage of Life is considered, in 
which individuals, particularly those at risk of health disparities, will achieve their 
optimal lifespan with the highest possible quality of health. This study collected data 
on healthcare providers providing preventative health services to consumers in four 
states at higher risk for future incidence and mortality from cervical cancer, namely 
those with increased proportions of low-income and minority women (Markowitz, et 
al., 2007). This study also focused on the influence of public policy, which is an 
essential aspect of public health, and individual healthcare provider attitudes and 
behaviors, who are the primary gatekeepers of access to vaccination services.  
Second, this study promoted the CDC goal of Healthy People in Healthy 
Places, particularly for Healthy Healthcare Settings, to increase the number of 
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healthcare settings that provide safe, effective, and satisfying patient care. By 
surveying healthcare providers regarding their perceived barriers to, and supports of, 
HPV vaccination, implications for improving patient care as well as increasing 
vaccination rates were drawn.   
Key Concept Definitions 
 As this study is focused on prevention and public health, there are important 
key concepts to define. The first is the term health care. According to Cowles (2000), 
health care involves “individual and societal efforts to prevent health problems from 
emerging and to maintain current levels of health” (p. 13). It involves both individual 
and societal responsibility, the latter entailing the provision and accessibility to 
resources and conditions that foster individual health promoting behaviors. The 
second term is primary care, which focuses on “the patient’s first entry into the 
health care system” (p. 95) and which carries out public health functions of primary 
prevention, such as immunizations. While primary care providers are typically 
working with the individual, social workers who take a public health approach are 
looking at the community and how to affect the policies and programs that are 
connected with service delivery and utilization. Primary care providers are charged 
with providing accessible care, working in partnership with patients, and taking into 
consideration the unique differences found in families and communities (Cowles, 
2000). 
A third important term is health behavior, which according to Coulton 
(1978), entails “behavior aimed either at the prevention of disease or at the detection 
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of disease in an asymptomatic state” (p. 297). This study is focused on the former part 
of the definition. Similar to this is the fourth term primary prevention, or “the altering 
of susceptibility to a disease or the reduction of exposure to causal agents for 
susceptible individuals” (Whitman & Hennelly, 1982, p. 28). Primary prevention is 
tied closely with epidemiological efforts that include identifying at-risk 
characteristics and groups for disease, studying group rather than individual data, 
finding the link between risk factors and disease etiology, and finally developing 
interventions that change group characteristics or behaviors as well as prevent 
infection by altering the environment. In connection with studying group data, a fifth 
term is population-at-risk, which includes “individuals who are both capable and 
likely to contract a condition, state, or disease” (p. 30). In this study, pre-adolescents 
and adolescents are the population-at-risk. 
The Institute of Medicine (IOM) defines the sixth term, quality of care, as 
“the degree to which health services for individuals and populations increase the 
likelihood of desired health outcomes and are consistent with current professional 
knowledge” (IOM, 1990, p. 80). This study seeks to improve access to, and the 
quality of, healthcare by better understanding healthcare providers’ attitudes and 
actions.  
Finally, a seventh term is Vaccines for Children (VFC), which is a federally 
funded vaccine assistance program available for youth aged 18 and younger who 
currently receive Medicaid or who are eligible for Medicaid (Dempsey & Davis, 
2006). It is also available for youth who are American Indians or Alaska natives, or 
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those youth who are underinsured and seek help at official VFC programs. Some state 
governments will allot extra money to providers in private practice to offer free 
vaccines for underinsured patients. According to Gudeman (2007), 27 percent of 
youth age 18 and under receive Medicaid benefits and 40 percent of vaccines for 
children are paid through the VFC program. Approximately 85 percent of 
pediatricians are registered to provide vaccines through the VFC program.  
Current State-Level HPV Policy Initiatives 
Since the release of Gardasil™, 41 states and the District of Columbia (D.C.) 
have initiated policies to promote the prevention of HPV and cervical cancer 
(National Conference of State Legislatures, 2008). Proposed policies have ranged 
from education and outreach about the prevalence and etiology of cervical cancer to 
HPV vaccination mandates for girls prior to school enrollment. Currently, 19 states 
have passed various policies, many of which concern providing funding for HPV 
education and vaccination. The most controversial policy proposed has been the 
vaccine mandate for school enrollment. Such a mandate typically would require all 
females entering a certain grade in both public and private schools to be vaccinated 
prior to school enrollment. Proposed school mandates have varying degrees of opt-out 
options for parents who may be opposed to vaccinating their children due to religious 
or other personal beliefs. The controversy regarding the school mandate stems around 
concerns of the cost of the vaccine for parents, level of funding provided by the state, 
as well as the safety and effectiveness of the vaccine. Additionally, arguments for 
parents’ rights, particularly regarding a vaccine preventing a sexually transmitted 
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infection (STI), and moral issues have been raised. Similar to the argument against 
comprehensive sexuality education, groups argue that offering education and 
providing the HPV vaccine will promote sexual promiscuity in girls (Charo, 2007).  
While 24 states and D.C. have initiated legislation that would require a 
vaccination mandate for school enrollment, none have been successful in passing it 
without either being withdrawn later or significantly delayed for a year or more 
(National Conference of State Legislatures, August 2008). The first most notable case 
was in Texas, where the governor’s executive order to mandate the vaccination of 
girls entering sixth grade was overturned by the legislature and a bill was passed to 
ban any future vaccine mandate for school enrollment. The second highly publicized 
case was in New Mexico, where conversely, the governor vetoed a vaccination 
mandate of girls ages 9 to 14 for school enrollment. In October 2007, Virginia 
achieved approval from both the legislature and the governor to carry out a 
vaccination mandate for girls entering sixth grade, however the implementation was 
to start in October, 2008. Since then, there has been a delay in implementation, as 
there has been a bill proposed to remove the mandate. In August 2007, a vaccination 
mandate for all females in 7th through 12th grades was proposed in New Jersey along 
with a public awareness campaign and distribution of information to parents. 
However, the bill passed without the vaccination mandate requirement, despite 
language in the bill that gave parents a great deal of maneuverability for opting out of 
the vaccination requirement.  
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Educational and financial initiatives have been faring better. For example, in 
North Carolina, legislation passed that required an educational fact sheet be given to 
all parents of youth in fifth through twelfth grades. Since the release of the vaccine, 
10 states have proposed policy initiatives that would urge or require some or all 
citizens’ health insurance coverage for the HPV vaccine. In five of those states, such 
bills have passed, including New Mexico, which requires health insurance coverage 
for girls ages 9 to 14 getting vaccinated.   
Other childhood vaccines, such as Measles, Mumps, and Rubella (MMR) and 
Hepatitis B, have become generally accepted and utilized by health providers 
throughout the country, particularly when vaccination mandates for school enrollment 
have been initiated at the state level (Rupp, Rosenthal, & Middleman, 2006). The 
introduction of the HPV vaccine coincides with a growing anti-vaccination movement 
within the U.S. over the increasing number of vaccines for children and adolescents 
(Wolfe, Sharp, & Lipsky, 2002). The HPV vaccine in particular has raised 
considerable discomfort, fear, and resistance by various groups and individuals, 
especially against any state policies mandating the HPV vaccine for girls’ school 
enrollment.  
For the purpose of this study, four types of state policy initiatives have been 
categorized1.  
 
1Given the dynamic nature of state policy, a caveat should be mentioned that the state 
policy initiatives were considered at the time of the start of the study. With the typical 
time lag that occurs from proposed legislation, to passing it, to actual implementation, 
it was naïvely expected that the state policy status would not change drastically 
during the relatively brief data collection period. 
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The first category includes those state policy initiatives that are aimed at increasing 
vaccination through educational outreach to the public. The second category includes 
those state policy initiatives where the aim is to provide financial support to patients 
who seek vaccination. The third state policy category includes those initiatives where 
the goal is to stop a HPV vaccine mandate for school enrollment. The final category 
includes those states who have not initiated any state policy initiative. 
Aim of Study and Research Questions 
In order to reduce the likelihood that vulnerable populations such as 
adolescents will experience the consequences of serious STDs, such as cervical 
cancer, social work must examine ways to improve access to preventive healthcare 
services and to collaborate with healthcare providers and public health professionals 
to develop ways to increase vaccination for those who do access services.  
As with any new immunization, healthcare providers are the primary 
gatekeepers for access to vaccination (Sturm, Mays, & Zimet, 2005). Moreover, HPV 
vaccination is a responsibility of healthcare providers all across the nation, some of 
whom may practice in states that establish legislation aimed at promoting vaccination. 
Considering that HPV vaccination is in its infancy, it is paramount to understand the 
factors that are associated with HPV vaccination decisions made by healthcare 
providers. With the Advisory Council on Immunization Practices (ACIP) targeting 
girls aged 11 and 12 (Markowitz, et al., 2007), and with evidence that suggests that 
young people are engaging in sexual activity in early to mid-adolescence (Charo, 
2007; Hopenhayn, Christian, Christian, & Schoenberg, 2007), the target population 
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for research becomes primary care providers who provide direct preventive services 
to pre-adolescent and adolescent girls.  
The release of the HPV vaccine and the emergence of state policies to 
improve HPV vaccination rates provide a timely and important research opportunity. 
This study takes a population-based focus in order to promote primary prevention by 
understanding the variations in healthcare provider attitudes and actions, and by 
uncovering the connection between health care policy and actual provider practice. It 
examines the context in which HPV vaccination services are provided and addresses 
critical public health research issues, specifically studying those providers who offer 
services to young women who belong to low-income and minority groups. This 
investigation studies a variety of healthcare settings and the interaction between 
provider behavior, state policy, and vaccination actions. Healthcare providers who 
serve consumers at higher risk for health disparities are of critical importance; 
consequently, the target population provides services to a large contingency of 
minority populations, including Latina, Native American, African American, and 
low-income women.  
Main Research Questions 
A) Are providers' HPV vaccination rates higher for girls aged 13 to 17 
compared with girls aged 9 to 12 in each state?  
Hypothesis: Providers’ vaccination rates will be significantly higher 
for girls aged 13 to 17 than for girls aged 9 to 12 in all four states.   
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B) Is type of state policy initiative associated with varying providers’ HPV 
vaccination rates for girls ages 9 to 12 and girls 13 to 17? 
Hypothesis: Providers’ HPV vaccination rates will differ significantly 
for both age groups, with states that mandate health insurance 
coverage for the vaccine having the highest rates and those with no 
policy initiative the lowest. 
C) What is the nature of the relationship between indicators of health care   
access and vaccination rates in both age groups?  
Use of private insurance and belonging to a non-minority racial 
background will be predictive of higher provider HPV vaccination 
rates in both age groups.   
D) What do healthcare providers identify as the most common barriers, 
supports, and HPV vaccination actions? Of the most common barriers and 
supports, which are reported as having the most impact on HPV vaccination 
actions? 
Hypothesis: The most common barriers will include the financial 
burden to the patient and concerns about negative perceptions of 
patients about the HPV vaccine. The most common supports will 
include believing the HPV vaccine will improve women’s lives, the 
state policy initiative, and the professional adherence to CDC 
recommendations. The most common actions will include counseling 
parents and seeking more information about the HPV vaccine.  The 
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financial burden will be reported as the most influential burden and the 
policy initiative will be the most influential support.  
E) Which combination of predictors, including type of state-initiated HPV 
vaccine policy, type of healthcare provider, and the vaccine barriers and 
supports perceived by healthcare providers, is most predictive of healthcare 
providers’ HPV vaccinations of girls aged 9 to 12 and girls aged 13 to 17? Is it 
the same combination for both age groups? 
Hypothesis: Provider’s HPV vaccination rates of girls aged 9 to 12 
will be higher in New Mexico, where there is mandated health 
insurance coverage for girls 9-14 who are vaccinated, among nurse 
practitioners and physician assistants, and among those with fewer 
perceived barriers and more perceived supports of HPV vaccinations. 
Provider’s HPV vaccination rates of girls aged 13 to 17 will be higher 
in New Mexico, among pediatricians and family physicians, and 
among those with fewer perceived barriers and more perceived 
supports of HPV vaccinations.  
Results are directly relevant to consumers, providers, administrators, 
state/local health departments and policy makers. The study provides pertinent 
information that may provide insight to states considering HPV policy initiatives, as 
well as healthcare organizations and providers who are interested in enhancing 
service delivery for patients interested in obtaining the HPV vaccination, and finally 
to healthcare social workers who work closely with providers and patients.  
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Chapter 2: Guiding Theory 
  
This study relies on theory to provide a foundation for guiding the 
development of the research questions and approach. A public health framework as 
well as the theory of planned behavior is utilized to inform the development of the 
study, both of which are embedded within a social welfare context.  
Positioning this Research within a Social Welfare Context 
 This research is grounded in a social welfare context that draws from a 
systems framework.  
Using a Social Welfare Systems Framework 
Much of social work uses a systems framework to understand social problems 
and to engage in social work interventions. On the continuum of social work arenas, 
human systems are connected in complex ways and need to be considered as a whole 
greater than the sum of its parts (Robbins, Chatterjee & Canda, 2006). In this view, 
individuals within society are constantly interacting with the outside environment, 
which creates the need for continuous adaptation from both individuals and the 
environment. In the context of this study, it is imperative to consider the influence 
and connection between the major actors in the system that that is being researched. 
This includes understanding the service target populations (i.e. young female patients 
and their parents), as well as those aspects within the environment that are 
interdependent with the service target populations (i.e., state policy, healthcare 
providers and the organizations that employ providers).  
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Within this framework, the ecological perspective enhances this 
understanding by recognizing the potential fluidity and level of fit between the 
environment and individuals (Germain, 1979). As social workers, we aim to enhance 
this fit between these two systems, so that both systems can adapt and shape one 
another, which leads to increased functionality. From this perspective, there are many 
opportunities for both systems to grow and reach their full potential. In this study, 
gaining an understanding for the “goodness of fit” during a time in which the systems 
(i.e. state policy and healthcare providers) may be undergoing a period of adaptation 
to the entrance of the new vaccine is paramount. Introduction of the HPV vaccine 
may create stress in the systems, particularly if there are incongruities between the 
needs and competencies within these systems. 
Shulman (1999) indicates that all social work models help to understand 
individuals and their environments. The author utilizes an interactional model, which 
has three core concepts. The first is the symbiotic relationship between individuals 
and their social worlds. The second is that obstacles routinely block the mutual need 
that exists between these actors, and the third concept is that both the individuals and 
their environments have strengths that can be capitalized upon to improve 
functioning. Using this model in the context of this research, the symbiotic 
relationship exists between state healthcare policies, healthcare organizations, their 
healthcare providers and their patients. All of these systems need one another in order 
to function well, however at times, barriers may inhibit their successful interaction. In 
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order to have a thriving relationship, strengths and supports within these systems 
must be identified.   
In a similar vein, Sheafor and Horejsi (2006) assert that an essential role of 
social work is to enhance social functioning, which they define as “a person’s ability 
to accomplish those tasks and activities necessary to meet his or her basic needs and 
perform his or her major social roles…” (p. 5). This study considers the current social 
functioning of healthcare providers in their social roles as gatekeepers to vulnerable 
patients needing medical counseling and services. Additionally, the goal of enhancing 
the social functioning for patients is directly linked to this study in considering the 
importance of patients’ access to medical care. One way to increase social 
functioning is to provide social care, which includes “actions and efforts designed to 
provide people in need with access to the basics of life…and opportunities to meet 
their psychosocial needs…” (p. 5). As social workers, we recognize that vulnerable 
populations, such as adolescents, need access to preventive healthcare services that 
have the potential to respond to their needs and maximize the length and quality of 
their lives. Identifying potential areas in which the environment can be modified to 
improve social functioning of the major actors is key. Patients’ immediate 
environment can affect social functioning; for this study, the immediate environment 
includes the healthcare system they access and the healthcare providers with whom 
they interact. The distant environment includes the state policies that are being 
implemented to support HPV vaccination; while this environment is broader in 
nature, it still may play a direct role in patients’ social functioning.  
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The systems framework highlights social workers’ practice within varying 
levels of systems, ranging from the micro to the macro level. This study is a form of 
social work macro practice, which Netting, Kettner, and McMurtry (2004) define as 
“professionally guided intervention designed to bring about planned change in 
organizations and communities” (p. 4). They assert that some problem areas require 
change to occur within the context of services provided, the programs providing the 
services, or the policies that influence the programs and services. When conducting 
macro practice, the authors assert that social workers must understand the problem, 
the population, and the arena (i.e. organizations and communities); it is where these 
areas overlap that is most important. The larger system, including the political and 
policy context, is also considered. This research looks at the problem (i.e. HPV), the 
service target population (i.e., adolescents and their parents), and the arena (i.e. 
healthcare providers), while considering the role of the policy context (i.e., current 
social policy initiatives). 
Using a Public Health Framework in the Social Welfare Context 
Understanding the various systems that interact within this study is enhanced 
when they are put into a public health framework. Interventions can occur at three 
points: 1) prior to the development of a problem, 2) when the problem is occurring, or 
3) after the problem has occurred. When efforts are focused primarily on prevention 
during these three phases, the social work interventions are then referred to as 
primary, secondary, and tertiary prevention. In discussing prevention, Sheafor and 
Horejsi (2006) write: 
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Many prevention efforts by social workers are concerned with improving the 
way people relate to and utilize available health and human services provided 
by the organizations that make up the social welfare and health care systems. 
At the same time, prevention efforts attempt to improve people’s access to 
these often complex, legalistic, and highly bureaucratic services and to 
enhance the quality of services obtained when one has access to them. (p. 8) 
Each phase requires a different understanding of the systems involved and the goals 
of change. For this study, primary prevention has been selected as the necessary 
intervention; a public health framework focuses on primary prevention and provides 
useful guidance in developing the research.  
Epidemiology is the study of the cause of disease infection, and thus, how to 
control it. According to Whitman and Hennelly (1982), the epidemiologic triangle is a 
basic causal model that illustrates the three factors involved in the manifestation of 
disease. These factors include the agent (e.g., HPV), the host (e.g., individual), and 
the environment (e.g., lack of education, lack of access to health care, concerns about 
talking with health provider, etc.). As gatekeepers to preventive health services, 
healthcare providers are an essential aspect of the environment. The social context 
that influences the decisions of healthcare providers and their service delivery to 
patients is considered paramount.  
An epidemiological health services research perspective identifies healthcare 
providers as a key component of the delivery of health services, playing a crucial role 
in the health status of patients (Oleske, 2001). Healthcare providers must take into 
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account the demographics, lifestyle, physical, social and economic environment of 
their patients. Additionally, healthcare providers must be able to recognize patient 
need and ability to utilize healthcare services. Providers’ perceptions of patient need 
are influenced by health information (e.g., the dissemination of practice guidelines) as 
well as diagnostic or treatment utilization restrictions imposed by health insurer or 
institutional policies. Patients’ ability to utilize healthcare services are influenced by 
healthcare provider accessibility, availability, knowledge, attitude and beliefs, which 
is the subject of this study.  
A public health perspective informs the importance of focusing on state policy 
as a central piece of this study. Wallack (1997) asserts that public health is the result 
of the interaction between various social arenas, such as economics, policies, 
communities, research and social movements. With the increasing shift of health 
policymaking to the states, it is likely that regional ideology, interest groups, and 
party control will have some impact on the creation and implementation of public 
policy (Shannon, 2001). This interaction between party and morality politics with 
public health goals has already begun with the deluge of state policy initiatives seen 
across the nation. It is within this social milieu that the study will occur, emphasizing 
the overarching goal of identifying policies that are most effective in promoting the 
population’s health.  
This study is also informed by the public health objectives set forth by federal 
government. In 1999, the US Public Health Service’s Core Public Health Functions 
Steering Commitment established Ten Essential Public Health Services, five of which 
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guide this study, namely to 1) inform, educate, and empower people about health 
issues; 2) mobilize community partnerships and action to identify and solve 
problems; 3) assure a competent public health and personal healthcare workforce; 4) 
evaluate effectiveness, accessibility, and quality of personal and population-based 
health services; and 5) search for new insights and innovative solutions to health 
problems (Shannon, 2001). 
The final public health perspective guiding this study is the consideration of 
the process that occurs when a new vaccine is introduced into the public. According 
to Matuszewski and Vermeulen (1994), there are five stages of a new technology’s 
life cycle: Phase 1: Investigation, Phase 2: Promotion, Phase 3: Acceptance and 
Utilization, Phase 4: Decline, and Phase 5: Obsolescence (as cited in Matuszewski, 
2001). In this case, the new technology is the HPV vaccine and this study will 
examine the outcomes of the first three phases, which will provide important 
information to stakeholders seeking to improve public health policy and maximize 
access to care among underserved populations.  
Using Social Psychology within the Social Welfare Context 
The social behavior of primary care providers as it relates to the vaccination 
of girls against HPV is vital because of the interaction between the various systems 
described above. Social psychology provides a foundation from which to understand 
what drives social behavior, particularly when it is connected with individuals 
engaging in health behavior or those individuals acting in ways that will promote the 
health of others. For both a provider and patient perspective, it is important to 
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consider the motivation behind health behavior as it relates to prevention of STDs. 
Fishbein and Guinan (1996) state this clearly in the following passage: 
Rather than basing a behavior change intervention upon possibly invalid or 
incorrect assumptions about behavior, scientists, clinicians, and public health 
workers should take advantage of the information that is currently available 
about behavior and its determinants…Clearly, the more one understands the 
factors influencing (or underlying) a person’s decision to perform (or not 
perform) a given behavior, the more likely one is to develop interventions that 
can effectively change that behavior. (p. 6)   
One theory that clearly delineates the process involved in individual decision-making 
is the Theory of Planned Behavior. It is the main substantive theory that provides a 
foundation for this study.  
Theory of Planned Behavior  
The Theory of Planned Behavior (TPB) has been repeatedly used in 
psychology and nursing to predict a variety of health behaviors, such as individual 
contraceptive use (Bryan, Fisher, & Fisher, 2002; Fazekas, Senn, & Ledgerwood, 
2001; Koniak-Griffin, Lesser, Uman, & Nyamathi, 2003; Reinecke, Schmidt, & 
Ajzen, 1996; Rye, Fisher, & Fisher, 2001; Villarruel, Jemmott, Jemmott, & Ronis, 
2004). Social work has also drawn from the TPB to predict a number of other 
behaviors. These include adolescent smoking (Maher & Rickwood, 1997); older 
adults’ participation in exercise (Bocksnick, 2004); adolescent gambling behavior 
(Wood & Griffiths, 2004); and academic success in African American youth (Davis, 
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Johnson, Cribbs & Saunders, 2002). Recently, the TPB has been used to guide survey 
development in studies exploring HPV vaccine acceptability by pediatricians (Kahn 
et al., 2005); however, it has not been widely used elsewhere in the HPV literature.  
The TPB is a direct extension of the Theory of Reasoned Action (TRA) 
(Ajzen & Fishbein, 1975). Both theories focus on predicting an individual's 
behavioral intentions, which are viewed as the immediate antecedents to actual 
behavior (Ajzen, 1985). The TPB accounts for the lack of complete volitional control 
an individual may have over the behavior in question (e.g., vaccination of girl against 
HPV). According to Ajzen, intentions are the “…indications of how hard people are 
willing to try…in order to perform the behavior” (1991, p. 181). A general 
proposition of the theory is that the stronger the behavioral intention, the greater the 
chance that the behavior will actually be carried out.  
 The TPB states that there are three antecedents to an individual’s behavioral 
intentions: personal attitudes, subjective norms, and perceived behavioral control 
(Ajzen, 1991). Personal attitudes develop out of an individual’s behavioral beliefs and 
are described as the “…degree to which a person has a favorable or unfavorable 
evaluation or appraisal of the behavior in question” (Ajzen, 1991, p. 188). Subjective 
norms are comprised of a person’s normative beliefs and are defined as “…the 
perceived social pressure to perform or not to perform the behavior” (p. 188). 
Perceived behavioral control forms out of an individual's control beliefs and refers to 
the “…perceived ease or difficulty of performing the behavior and it is assumed to 
reflect past experience as well as anticipated impediments and obstacles” (Ajzen, 
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1991, p. 188). Ajzen likens perceived behavioral control to Bandura’s (1986) 
principle of self-efficacy. This construct can also act as a proxy for “actual” control, 
which allows it to influence behaviors independently from behavioral intentions. 
Ajzen (1991) indicates that personal attitudes, subjective norms, and perceived 
behavioral control will have varying influence depending on the behavior and 
situation.  
Strengths of the Theory of Planned Behavior 
First, the TPB has been successful in predicting behavioral intentions towards 
a variety of behaviors. Second, Ajzen (1991) stated that salient beliefs must be 
understood according to the population and context in question. It is reasonable to 
posit that salient beliefs of primary care providers are unique and warrant attention. 
Third, the TPB is parsimonious (Sutton, 1998), which allows it to be accessible to a 
wide audience, as well as easily utilized within a new context, such as HPV 
vaccination. 
Limitations of the Theory of Planned Behavior 
The primary limitation of the TPB is its assumption of rational behavior. 
Ajzen indicates that individuals will use available information to make informed 
decisions (Ajzen & Fishbein, 1980). This assertion is based on a male-oriented, 
individualistic standard of what defines “rational” behavior. It does not consider 
specific gender or cultural differences that could alter what “rational” behavior means 
for minority healthcare providers or for understanding the behavior of minority 
patients. While the TPB considers the influence of referent groups on subjective 
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norms, ultimately an individual will only be affected to the extent to which the 
individual is motivated to comply with that referent group (e.g., such as other 
pediatricians) or individual (e.g., a patient) (Ajzen & Fishbein, 1972). This leaves 
possible conflicts in decision-making when normative beliefs from referent groups or 
individuals disagree (e.g., a nurse practitioner who follows ACIP recommendations 
but has a parent with a strong religious concerns about HPV vaccination or mistrust 
of vaccinations).  
Considering the Theory of Planned Behavior to Inform the Research 
 The primary components of the TPB are used to inform the basis for this 
study. The central premise that a primary care provider’s perceived barriers and 
supports, which stem from personal or normative beliefs, or perception of perceived 
behavioral control, leads to planned behavior is the foundation for the survey that has 
been developed for this study. While this initial study is looking at associations rather 
than causation, by understanding which barriers and supports are most frequently 
reported in relation to personal and normative beliefs, it will be feasible for future 
studies to test the extent to which the constructs of the TPB account for HPV 





Chapter 3: Review of the Literature 
 
The Role of Barriers and Supports in Social Work Research 
 The social work literature shows the essential link between barriers and 
supports within primary prevention. According to Coulton (1978), as supports are 
enhanced and barriers are reduced, preventive health behavior will increase. 
Specifically, she indicates that, “…planning for social work intervention should start 
with an assessment of the supports and barriers characteristics of given patients or 
target populations and their environments” (emphasis added) (p. 306). The barriers in 
the environment include the personal and professional barriers identified by primary 
care providers. These can include both personal or psychological barriers, such as fear 
and embarrassment and concerns about patient perceptions, as well as structural 
barriers to service provision, such as lack of information or financial constraints 
(Cowles, 2000). 
 Similarly, the supports of the environment include the personal, social, and 
professional supports enjoyed by primary care providers. Coulton (1978) writes that 
social supports are a “powerful determinant of health” (p. 101) and as such, primary 
care providers can be considered as a source of social support for patients and family 
members when they provide the needed information, counseling, and resources to 
families in an informed, open, and supportive manner.  
By understanding the barriers and supports faced by primary care providers as 
they relate to HPV vaccination in girls aged 9 to 12 and 13 to 17, specific 
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recommendations for interventions aimed at improving service delivery and 
utilization can be made in the future. Given the limited research on actions, it is 
unknown how the perceived barriers and supports of healthcare providers will 
influence their behaviors and in what directions those relationships will take, thus 
forming the basis of this investigation.  
Barriers and Supports Related To HPV Vaccination 
Given that trials for the HPV vaccine started in the 1990s, there is a finite 
amount of literature on this specific topic. In 2008, the first literature on actual 
vaccination rates started to appear; there have been two articles of this nature thus far. 
The majority of the literature, prior to 2008, has focused on the examination of 
attitudes, beliefs, and intentions regarding the HPV vaccine in hypothetical situations 
of vaccinating. The studies typically focused on healthcare providers, mothers of 
young girls, and women. From these studies, expected barriers, supports and 
intentions related to HPV vaccination were revealed. While the proposed study 
examined the current vaccination behaviors of providers, perceptions of current 
barriers and supports were also a key aspect of the research.  
Barriers Related to HPV Vaccination 
 There are a variety of different forms of barriers discussed in the literature. 
They have been separated into their common categories in this section. All of the 
categories discussed below have been reported in the strongest studies.  Frequently 




Lack of information/education has been discussed as a barrier to HPV 
vaccination, for young women, mothers of adolescent girls, as well as primary care 
providers, namely family physicians, pediatricians and nurse practitioners (Chan, 
Cheung, Lo, & Chung, 2007; Hoover, Carfioli, & Moench, 2000; Lazcano-Ponce, et 
al., 2001; Mays, Sturm & Zimet, 2004; Olshen, Woods, Austin, Luskin, & Bauchner, 
2005; Tedeschi, et al., 2006; Woodhall, et al., 2007; & Zimet, et al., 2000). Studies 
commonly revealed that parents and young women often are unfamiliar with the risks 
of contracting HPV or with its direct connection to cervical cancer. For example, in 
one of the more rigorous studies that used a cross-sectional telephone survey that 
included 2,000 women and men in Southern Australia, only two percent of the sample 
knew the etiology of cervical cancer (Marshall, Ryan, Roberton, & Baghurst, 2007). 
In a smaller study in the Netherlands, only one third of parents (N = 356) of 10 to 12 
year old children had heard of HPV and less than 15 percent were aware of the 
connection between HPV and cervical cancer (Lenselink, et al., 2008). Lack of 
information may also inhibit providers as well. In a much smaller study with 37 
primary care providers in New Mexico, Sussman, et al. (2007) found that barriers to 
counseling parents on HPV vaccination included limited knowledge of HPV and the 
low levels of knowledge by adolescents. As such, most studies provided participants 
with some form of brief educational intervention such as an informational sheet or 
pamphlet, which typically enhanced willingness to get vaccinated. Throughout the 
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literature, researchers recommended continued educational outreach and interventions 
for parents, women, and healthcare providers.  
Safety and Efficacy Barriers 
There have been concerns by parents, young women, and primary care 
providers about issues of vaccine safety and efficacy. In a recent study from the 
Netherlands, 1367 women randomly surveyed indicated concerns about both long-
term safety and effectiveness of the HPV vaccine as barriers to vaccination (Korfage, 
Essink-Bot, Daamen, Mols, & van Ballegooijen, 2008). In another strong study that 
included 513 pediatricians using a mail survey, pediatricians reported concerns about 
the safety of the vaccine and uncertainty regarding the efficacy of the vaccine in 
terms of its length of protection for individuals (Kahn, et al., 2005). Part of this 
uncertainty may be related to lack of up-to-date information, as one five-year 
longitudinal study showed that Gardasil™  is effective for at least five years, perhaps 
even longer (Gudeman, 2007). Though not found in an actual research study, the lack 
of full protection provided by the vaccine for other types of HPV beyond four 
types/strains—which are responsible for 70 percent of cervical cancer cases and 90 
percent of genital warts cases –has been noted by primary care providers (Dempsey & 
Davis, 2006). In an editorial piece, Gostin and DeAngelis (2007) assert that 
healthcare providers should be concerned about the lack of efficacy trials for girls 
aged 9 to 15 and recommend more trials before mandating the vaccine for school 
enrollment. Additional concerns by parents and young women focused on potential 
side effects from the vaccine and general safety of the vaccine (Gerend, Lee, & 
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Shepherd, 2007; Marshall, Ryan, Roberton, & Baghurst, 2007; Woodhall, et al., 
2007).  
Cultural Barriers 
Potential cultural barriers discussed in the literature have focused on race, 
ethnicity, socioeconomic status, education level and health insurance status (Sussman, 
et al., 2007). In a recent study that conducted a series of focus groups with 54 
Hispanic women in New Mexico, participants indicated that providers should 
consider relevant cultural issues related to HPV infection and the importance of the 
vaccine (Vanslyke, et al., 2008). Such issues included understanding that Hispanic 
men may put their partners at heightened risk for HPV due to the cultural tolerance of 
refusing to wear condoms and by engaging in sexual activities outside of their 
intimate relationship. In a qualitative study with 31 pediatricians, Tissot, et al. (2007) 
found that pediatricians had concerns about parents’ anti-vaccination beliefs, 
particularly for those parents who have strong religious beliefs or those who believe 
in holistic approaches to healing, as well as different racial/ethnic groups such as 
Latino, Asian, and Indian populations.  Further, African Americans were considered 
less trusting of medical providers and vaccines. Socioeconomic factors were also 
brought up, indicating that less education and income might decrease parental ability 
(i.e., access to care) to seek vaccine but that those with higher income and education 
may not see their children as vulnerable. Issues of higher income and lower education 
status were also found to be barriers to intentions in other studies as well, in which 
having a high income for parents was a perceived barrier to vaccination and low 
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education was a barrier for youth (Hopenhayn, Christian, Christian, & Schoenberg, 
2007; Woodhall, et al., 2007). 
Psychological Barriers 
Psychological barriers include personal concerns or discomfort with HPV 
vaccination. These barriers fall into two major categories: 1) concerns by primary 
care providers about the attitudes of parents due to the vaccine preventing an STI, and 
getting parental consent (Dempsey & Davis, 2006; Kahn, et al., 2005; Sussman, et al., 
2007); and 2) the concern by parents and young women that HPV vaccination would 
encourage promiscuity or that there was little personal risk of HPV infection for 
themselves or their adolescents (Marshall, Ryan, Roberton, & Baghurst, 2007; 
Woodhall, et al., 2007). 
Financial Barriers 
Gardasil ™  is the most expensive vaccine that is recommended for children 
and adolescents—selling for $360 as compared with under $50 for other 
recommended vaccines (Gudeman, 2007). It is not surprising then, that concerns 
about the financial burden of the vaccine have been brought up in the literature. 
Women report that having health insurance may not necessarily make the vaccine 
affordable if their health insurance company does not cover the vaccine either fully or 
partially (Hopenhayn, Christian, Christian, & Schoenberg, 2007). This sentiment is 
affirmed in a recent article with a sample of low-income women, which found that 
out of 409 women, only 42 percent indicated that they could afford the vaccine (Kahn 
et al., 2008).  
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Additionally, concerns about the constraints of the Vaccines for Children 
(VFC) program have arisen. There is considerable financial burden for primary care 
providers purchasing the vaccine at full cost for those who do not qualify for the VFC 
program, as well as for those providers who are not officially registered as a VFC site 
(Dempsey & Davis, 2006). Providers are taking a financial risk by purchasing the 
vaccine for private insurance patients, as their patients may not choose to be 
vaccinated because of the remaining financial burden. Providers may not recoup their 
investment if insurance companies only reimburse for the vaccine itself, and not for 
administrative and storage costs. As a result, some providers are reportedly keeping 
their vaccine supply low as a cautionary measure and only offering to those patients 
whose coverage will provide greater reimbursement (Gudeman, 2007).  
Further barriers exist for underinsured and privately insured youth. Gudeman 
(2007) asserts that while the VFC program offers relief to underinsured adolescents, 
there is limited access to the VFC discounts due to the lack of presence of Federally 
Qualified Health Centers (FQHC) or a Rural Health Clinics (RHC) in some 
geographic areas. Additionally, VFC benefits are not available to privately insured 
youth. Private insurance has typically been a source of support for patients in 
deferring vaccine costs; almost half of the recommended vaccines are normally 
covered by insurance companies. For those individuals whose health insurance plans 
do not provide coverage or have large deductibles, patients will face a financial 
burden. As such, policy aimed at increasing vaccination by requiring health insurance 
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companies to cover the vaccine will not be effective unless providers can reduce the 
initial cost to purchase the vaccine (Gudeman, 2007). 
 Compliance Barriers 
 Unlike many vaccines that only require one shot, Gardasil™ requires a three-
dose series, at zero, two, and six months (McIntosh, Sturpe, & Khanna, 2008). This 
may present a compliance challenge, particularly for vulnerable populations who 
have limited transportation and ability to take off work repeatedly (Herzog, Huh, 
Downs, Smith, & Monk, 2008). Requiring three visits can place an added burden on 
both the patient and the physician in terms of scheduling, availability, as well as 
limits placed on the number of visits covered for adolescent well-visits (McIntosh et 
al., 2008). Getting to the providers’ office may not be the only compliance challenge. 
Brabin and colleagues (2008) found adherence to be a barrier even when the vaccine 
was provided within the school setting, as students commonly missed their scheduled 
appointments to receive the first and second doses (16 and 24 percent, respectively); 
the 3rd dose was not discussed in this study, but it is reasonable to expect missed 
appointments given the pattern for the first two doses.  
Supports Related to HPV Vaccination 
Similar to barriers, there have been recurring supports mentioned in the 
literature as potentially enhancing HPV vaccination. There is less knowledge about 
the types of supports that would aid HPV vaccination. In the most rigorous studies, 
financial supports, health behavior, and state policy supports were reported as 
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perceived supports. Other supports reported in less rigorous studies included 
physician recommendations and organizational supports. 
Financial Supports 
As discussed earlier, the financial burden of the HPV vaccine has been a 
concern and thus providing financial support to primary care providers and patients is 
important. Providers, women, and parents have indicated that having the vaccine 
covered fully by insurance is key, as is making it affordable for those without 
insurance (Hoover, Carfioli, & Moench, 2000; Fazekas, Brewer, & Smith, 2008; 
Kahn, et al., 2005; Tedeschi, et al., 2006; Zimet, et al., 2000). According to Gudeman 
(2007) other forms of financial support may be capitalized upon, as 15 states provide 
universal vaccine coverage for required vaccines for all children, regardless of 
insurance or VFC status. States can use also federal CDC money to pay for 
underinsured patients to cover vaccine costs under Section 317 of the Vaccination 
Assistance Act of 1962 (Rein, Honeycutt, Rojas-Smith, & Hersey, 2006), which is 
given to support local and state vaccine programs. Interestingly, in a random-digit 
phone survey of over 600 women in Kentucky, having less income was seen as an aid 
to vaccination, perhaps because of their access to VFC programs (Hopenhayn, 
Christian, Christian, & Schoenberg, 2007).  
Though less rigorous, in one study utilizing a convenience sample drawn from 
a rural area of North Carolina, 146 women reported that they would be willing to pay 
on average a $178 of out-of-pocket cost for their daughters to get vaccinated 
(Fazekas, Brewer, & Smith, 2008). In the Netherlands, having the vaccine offered 
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free of charge through a national vaccination program was reported as a support in the 
sample of 356 parents of children aged 10 to 12 years (Lenselink, et al., 2008). In a 
less rigorous study that used qualitative methods with 34 parents, lower formal 
educational levels, which is typically associated with the use of public funding, also 
was associated with positive vaccination intentions (Mays, Sturm, & Zimet, 2004).  
Organizational Supports 
A variety of organizational supports, meaning supports provided by primary 
care settings such as clinics and private practices, have been discussed. Creating 
office supports, such as decreasing time constraints when visiting patients and 
providing necessary information/education to providers, has been discussed by 
primary care providers (Chan, Cheung, Lo, & Chung, 2007; Sussman, et al., 2007). 
In the small qualitative study with 31 pediatricians by Tissot, et al. (2007), 
potential supports for improving delivery of the HPV vaccine were discussed in 
depth. These supports included: 1) increasing feasibility of vaccine administration; 2) 
creating office protocols for increasing vaccination; 3) increasing access to the 
vaccine; 4) getting influential organizations to endorse the vaccine; and 5) providing 
education to providers, parents, and youth. Specific supports included provided 
lectures and written materials, such as informational sheets and professional 
organization policy sheets; local expert guest speakers, web sites with information 
and recommendations, data on HPV prevalence, susceptibility for patients, HPV-
related diseases and health impact; and also strategies for talking with parents and 
youth in a culturally sensitive way, such as providing scenarios and scripts. Also, 
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providing written material in the office, educational videos and web-based 
information for parents and youth were identified as potentially supportive.  
Provider Encouragement and Recommendation as a Support 
Primary care providers are typically seen as gatekeepers to health care 
services. One of the main reasons for this is the continued response by patients and 
their family members that having a provider recommend a particular service is 
influential in actually obtaining that service. HPV vaccine acceptability by parents 
and young women has been higher when they perceive that their health provider 
recommends the vaccine (Gerend, Lee, & Shepherd, 2007; Hoover, Carfioli, & 
Moench, 2000; Tedeschi, et al., 2006; Zimet, et al., 2000).  
Additionally, not only the recommendation, but also counseling by providers 
to patients and their families is seen as supportive of vaccination intentions (Adams, 
Jasani, & Fiander, 2007). Sussman, et al. (2007) found four factors to be important in 
the counseling process: 1) the importance of rapport building with adolescents; 2) the 
assumption that adolescents will engage in high-risk behaviors; 3) the difficulty and 
complexity of counseling about the HPV vaccine; and 4) the attitudes of primary care 
providers, nurse practitioners, and community acceptance of the HPV vaccine. 
State Policy Supports 
Given the past successes of mandating other major immunizations, such as 
Hepatitis B and Measles, Mumps, and Rubella (MMR), it is expected that primary 
care providers will have informed attitudes regarding the utilization of state HPV 
vaccination mandates for school enrollment. In the rigorous study with pediatricians 
 46
(Kahn, et al., 2005), discussed in the barriers section, mandating the HPV vaccine for 
school registration was considered to be essential for increased vaccination of youth. 
Tissot, et al. (2007) found that out of 31 pediatricians, most recommended a universal 
vaccine over a targeted vaccine. Interestingly, one third supported a vaccination 
mandate for school enrollment, one third disagreed with a mandate, and the other 
third were undecided but believed a mandate was not likely to occur.  
Health Behavior as a Support 
Some interesting past and current health behaviors have also been found to be 
potentially supportive of HPV vaccination. In a randomized study of 880 Mexican 
women completing in-person surveys, having multiple partners was reported as an aid 
to HPV vaccination (Lazcano-Ponce, et al., 2001). Gerend, Lee, and Shepherd (2007) 
found that underserved low-income women perceived prior HIV testing as a support 
for future vaccination against HPV. The authors speculated that prior preventive 
health behavior would be a supportive function of future behavior as well as an 
increased knowledge base about STD’s and STI’s in general. Additionally, present 
health concerns may be indicative of vaccine acceptability. Hopenhayn, Christian, 
Christian, and Schoenberg (2007) found that women who smoked were more in favor 
of vaccination than those who did not smoke. The authors attributed this finding to 
the increased risk factor for cervical cancer that exists for smokers. In a similar vein, 
in a study surveying a random sample of 1,350 Canadian parents of children aged 8 to 
18 years old, knowing a friend or relative who was perceived as being at risk for 
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cervical cancer was viewed as a support of vaccination for parents (Ogilvie et al., 
2008).  
Initial HPV Vaccination Rates 
 As stated earlier, articles describing actual HPV vaccination rates within the 
U.S. and abroad have only just begun to be published. As a general statement on 
vaccination, the Advisory Committee on Immunization Practices (ACIP) has reported 
that since March 2007, nearly five million doses of the HPV vaccine have been given 
in the U.S. (Herzog, Huh, Downs, Smith, & Monk, 2008). The Advisory Committee 
on Immunization Practices (ACIP) has broken this down into two age groups; they 
report that 75 percent of those doses have gone to those aged 9 to 17, with the 
remaining 25 percent going to those 18 to 26 years old. However, ACIP did not 
partition it down further within the 9 to 17 age group, which would be particularly 
important for this study.  
 On a smaller scale, there have been two studies reporting initial vaccination 
rates by patients. One was completed in England, where 36 secondary schools were 
offered the opportunity to have 12 and 13 year old girls vaccinated against HPV. The 
physicians used Cervarix™, which is the bivalent vaccine used currently in Europe, 
as opposed to Gardasil™, which is the quadvialent vaccine used in the U.S. (Brabin et 
al., 2008). Within the school setting, primary care physicians administered the 
vaccine the three doses at zero, one, and six months, which is the standard protocol 
for giving Cervarix™ . In this study, 2817 girls were offered the vaccine; from this 
sample, 70 percent completed both the first and second doses of the series. The 
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vaccination uptake for the third dose was not reported, which is important given that 
the effectiveness of the vaccine is only assured when all three doses are administered. 
Interestingly, there were significantly lower vaccination rates at those schools that 
either had greater percentages of ethnic minority students or had higher percentages 
of students eligible to receive free meals.  
 The second article focused on a sample of low-income young women ages 13 
to 26 who were accessing services at three primary care clinics (Kahn et al., 2008). 
They sampled 409 sexually experienced females who completed a survey that asked 
for a self-report of HPV vaccination among other questions, as well as a DNA test for 
HPV strains. Of those approached, 98 percent participated in the study. Only 5 
percent of the sample reported receiving the first dose of the vaccine and less than 1 
percent had received the entire series. The authors reported that low vaccination rates 
may have been due to multiple factors, including the health department not offering 
the vaccine until after the study began, limited financial benefit for clinics to offer the 
vaccine to low-income women, and perceived and actual barriers for both patients 
and organizations. The study did not look at a comparison group of pre-adolescent, 
non-sexually experienced girls accessing primary care services, which would have 
been useful for this research.  
Intentions Related to HPV Vaccination 
 Throughout the literature, intentions to vaccinate against HPV have been quite 
high regardless of being a provider, a parent, or a young woman (Hopenhayn, 
Christian, Christian, & Schoenberg, 2007; Marshall, Ryan, Roberton, & Baghurst, 
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2007). In a survey completed by 400 adolescents and 740 parents, 83 percent and 86 
percent favored HPV vaccination respectively (Woodhall et al., 2007). However, 
those intentions have been markedly lower when considering vaccination for younger 
girls. For providers, family physicians, nurse practitioners, and pediatricians typically 
supported vaccination for older adolescents compared to their younger counterparts 
(Mays & Zimet, 2004; Riedesel et al., 2005). In surveying 513 pediatricians, Kahn, et 
al. (2005) found that while most thought that youth between 9 and 13 should be 
targeted for the vaccine, more were likely to recommend the vaccine for those older 
than 13 years old.  
 The same pattern has been found with mothers and young women. While a 
majority are interested in the vaccine for their daughters or themselves, the age of a 
child being vaccinated is an important consideration (Fazekas, Brewer, & Smith, 
2008; Hopenhayn, Christian, Christian, & Schoenberg, 2007; Mays, Sturm & Zimet, 
2004; Olshen, Woods, Austin, Luskin, & Bauchner, 2005). For example, Fazekas and 
colleagues (2008) found that from 146 parents in a rural North Carolina region, there 
were lower levels of intentions to vaccinate if the child was between the ages of 11 to 
16 (38 percent) versus 17 to 25 (43 percent). Intentions for vaccinating girls age nine 
and ten years old were not discussed. In the only study that had 100 percent of low-
income women expressing acceptability towards getting their child vaccinated, the 
researchers who surveyed the 58 women did not ask if the age of the child influenced 
their intentions (Gerend, Lee, & Shepherd, 2007).  
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Internationally, there have been both positive and negative reactions by 
parents to vaccinating pre-adolescents. Two articles in the Netherlands show positive 
intentions to vaccinate pre-adolescent girls ages 10 to 12 years in age (Korfage, 
Essink-Bot, Daamen, Mols, & van Ballegooijen, 2008; Lenselink et al., 2008). The 
more rigorous of the two, which sampled 1367 women, reported that on average, 78 
percent of the women would vaccinate their 10-year-old daughter or granddaughter. 
In the other study, of 356 parents of 10 to 12 year olds, almost 90 percent reported 
favorable intentions to vaccinate their daughters if the vaccine was provided at no 
cost through the government. This connection between high intentions to vaccinate 
girls through a free government program was also found in a recent study done in a 
random sample in Canada with 1350 parents of children ages 8 to 18 years of age 
(Ogilvie et al., 2008). From the sample, over 70 percent of parents indicated a 
positive intention to have their daughters vaccinated in such a context.  
On the negative side, in a study surveying 170 mothers in Hong Kong, parents 
most frequently reported support for vaccinating girls in ninth grade or above, as 
compared with a little less than one fourth of the mothers supporting vaccination of 
girls in sixth grade (Chan, Cheung, Lo & Chung, 2007). This may be a reflection of 
differing social norms and values between these cultures around sexual behaviors. 
This idea is supported by Widmer, Treas, and Newcomb (1998), who examined 
national survey data from 24 countries on attitudes about sexual behaviors and found 
that both the Netherlands and Canada report greater acceptance of premarital sex in 
comparison to Japan and the Philippines.  
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Future Directions for Research 
The literature reviewed indicates that the knowledge of perceived barriers is 
grounded in more rigorous research than that for supports. Several categories of 
perceived barriers have been reported in studies with large samples of surveyed 
healthcare providers, mothers, and young women. These barriers include 
informational barriers, safety and efficacy barriers, financial barriers, cultural 
barriers, and psychological barriers. Less is known about perceived supports, though 
survey research suggests that financial supports, health behaviors, and state supports 
are important aids to vaccination, but less is known about physician recommendation 
supports and organizational supports. While the literature regarding intentions is 
consistent in both strong and weak studies, the main weakness within this area is that 
a majority of the studies focus on intentions rather than actions. The next logical step 
in this field of research is to capture behaviors.   
This study is also informed by a recent review article that provides 
recommendations for future HPV research (Zimet, Liddon, Rosenthal, Lazcano-
Ponce, & Allen, 2006). The authors indicated that the studies carried out thus far have 
struggled with various limitations, including low sample sizes and response rates, 
convenience samples, an inconsistent use of theory, and hypothetical scenarios. 
Consequently, it is essential to look at primary care providers’ current perceptions of 
barriers and supports now that the vaccine has been on the market for over two years 
and with the influx of new state policies aimed at promoting vaccination. Moreover, 
while most of the literature written both prior and now after the release of the HPV 
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vaccine is focused on intentions, it is important to examine the actual behaviors of 
healthcare providers regarding HPV vaccination, particularly for pre-adolescent and 
adolescent girls. By taking this approach, this study goes beyond prior attitudinal 
research by specifying the actual perceived barriers, supports, and behavioral actions 


















Chapter 4: Research Design and Methodology 
 The literature review and theoretical perspectives discussed in the prior 
chapters inform the research design and methodology of this study. In this chapter, a 
detailed description of the conceptual and procedural aspects of the research study is 
presented. This includes the re-statement of the main research questions, along with 
sampling and data collection procedures, as well as variable definitions. This is 
followed by a discussion of the reliability and validity of the survey, along with a 
description of methodological challenges presented by the study. The chapter 
concludes with a summary of how each research question is answered through 
specific statistical analyses.  
Main Research Questions 
This study poses research questions that focus on perceptions and actions of 
health care providers. The aim of the research questions is to provide knowledge 
regarding the connection between social policy, human behavior, and the control of 
HPV.  
A) Are providers' HPV vaccination rates higher for girls aged 13 to 17 
compared with girls aged 9 to 12 in each state?  
Hypothesis: Providers’ vaccination rates will be significantly higher 
for girls aged 13 to 17 than for girls aged 9 to 12 in all four states.   
B) Is type of state policy initiative associated with increased providers’ HPV 
vaccination rates for girls ages 9 to 12 and girls 13 to 17? 
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Hypothesis: Providers’ HPV vaccination rates will differ significantly 
for both age groups, with states that mandate health insurance 
coverage for the vaccine having the highest rates and those with no 
policy initiative the lowest rates. 
C) What is the nature of the relationship between indicators of health care 
access and vaccination rates in both age groups?  
Use of private insurance and belonging to a non-minority racial 
background will be predictive of higher provider HPV vaccination 
rates in both age groups.   
D) What do healthcare providers identify as the most common barriers, 
supports, and HPV vaccination actions? Of the most common barriers and 
supports, which are reported as having the most impact on HPV vaccination 
actions? 
Hypothesis: The most common barriers will include the financial 
burden to the patient and concerns about negative perceptions of 
patients about the HPV vaccine. The most common supports will 
include believing the HPV vaccine will improve women’s lives, the 
state policy initiative, and the professional adherence to CDC 
recommendations. The most common actions will include counseling 
parents and seeking more information about the HPV vaccine.  The 
financial burden will be reported as the most influential burden and the 
policy initiative will be the most influential support.  
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E) Which combination of predictors, including type of state-initiated HPV 
vaccine policy, type of healthcare provider, and the vaccine barriers and 
supports perceived by healthcare providers, is most predictive of healthcare 
providers’ HPV vaccinations of girls aged 9 to 12 and girls aged 13 to 17? Is it 
the same combination for both age groups? Are there interaction effects 
between the predictors?  
Hypothesis: Provider’s HPV vaccination rates of girls aged 9 to 12 
will be higher in New Mexico, where there is mandated health 
insurance coverage for girls 9-14 who are vaccinated, among nurse 
practitioners and physician assistants, and among those with fewer 
perceived barriers and more perceived supports of HPV vaccinations. 
Provider’s HPV vaccination rates of girls aged 13 to 17 will be higher 
in New Mexico, among pediatricians and family physicians, and 
among those with fewer perceived barriers and more perceived 
supports of HPV vaccinations.  
Methodological Procedures 
 The various methodological procedures are described in detail in this section, 
with sections covering sampling procedures, types and sources of data collected, 
methodological problems encountered, the reliability and validity of the measure, 





This study used a cross-sectional survey with randomly selected primary care 
providers who were likely to provide vaccination services to girls between the ages of 
9 to 17, specifically family physicians, pediatricians, physician assistants (PAs), 
gynecologists, and nurse practitioners (NPs). By including NPs in the sample, there 
was increased representation of women providers in the study. Incorporating PAs was 
also important, as it was a population of primary care providers not yet included in 
the HPV literature.  
Samples of primary care providers from New Mexico, North Carolina, Texas 
and Louisiana were selected due to state variations in policy initiatives, as well as the 
demographic characteristics of each state, and patient access to providers. State policy 
initiatives are described below based on the strength of the initiative, that is, which 
initiative is thought to have the strongest relationship with increased HPV vaccination 
rates.  
First, in 2007, New Mexico’s legislature passed a mandate (S.B. 1174) 
requiring all girls between the ages of 9 to 14 be vaccinated prior to school 
enrollment, with distribution of information to parents. The Governor vetoed that 
legislation shortly thereafter (National Conference of State Legislators, 2008). Later 
that year, the legislature successfully passed Senate Bill 407, which required that all 
health insurance companies provide coverage for the HPV vaccine for girls between 
the ages of 9 and 14, with typical deductible and coinsurance protocols in place. 
Given that the literature has identified the financial burden of the vaccine to be a 
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potentially large barrier, this policy initiative was considered the strongest of the four 
states. This policy initiative will be labeled “health insurance coverage”.  
Second, in July 2007, North Carolina passed legislation (S.B. 260) that 
required the state Health Department to disseminate educational fact sheets on HPV 
and the vaccine to all parents of children in fifth through twelfth grades, starting in 
the 2007-2008 school year (National Conference of State Legislatures, 2008). As 
stated in the literature review, increased education about HPV and the vaccine was 
linked to increased intentions to vaccinate, thus putting it as the second strongest 
policy initiative. This policy initiative will be labeled “educational fact sheets to 
parents”.  
Third, in February 2007, the governor of Texas signed an executive order 
requiring all girls entering sixth grade to be vaccinated against HPV prior to entering 
school the next year (National Conference of State Legislatures, 2008). This order 
was countermanded by the legislature (H.B. 1098), such that no state mandate for 
vaccination prior to school enrollment, either for elementary or secondary education, 
would be allowed. This legislation also required that schools provide parents with 
correct and scientific information about HPV vaccine at the time the vaccine is 
recommended on the immunization schedule, which is the timetable by age for when 
youth should get vaccinated (i.e., 11 or 12 years old for girls or 13 to 18 if not already 
vaccinated) (CDC, 2008). However, since there is no school requirement for the 
vaccine in Texas, this latter point was not enforceable (L. Garcia, personal 
communication, December 11, 2008).  
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Additionally in September 2007, the Texas legislature passed a bill (H.B. 
1379) that required the state Department of Health to create and disseminate 
education on HPV and the vaccine for English and Spanish speaking populations. The 
law required that information on the efficacy, accessibility, and contraindications of 
the vaccine are included in the materials. According to Lupe Garcia with the Texas 
Department of Health, this legislation did not come with any appropriation of money, 
thus they were left with providing education at no additional cost to the taxpayers 
(personal communication, December 11, 2008). The implementation of this 
legislation involved putting educational fact sheets on their website, as well as 
distributing education to all school nurses across the state in public schools, and any 
private nurses who selected to receive the educational materials. Additionally, the 
Texas Department of Health created a network of internet links both on their website 
and with other state and national institutions that provide education on HPV and the 
vaccine. This policy initiative will be labeled “Bilingual education—Not 
Appropriated and Ban on Mandate”.  
Finally, Louisiana, which has not had any state HPV policy passed, served as 
a control state. Given that the literature shows an increase in vaccination when state 
policies are passed, such as vaccine mandates for school enrollment, not having any 
state policy was considered the weakest among the four states. This policy initiative 
will be labeled “no policy initiative”.  
This researcher used a purposive sampling strategy in selecting the four states 
in the study. The four states were selected not only for their differing policy 
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approaches to the HPV vaccine, but for their known demographics and 
socioeconomic characteristics that are typically correlated with lower access to 
healthcare, which suggests that access to care is an issue in these states. States were 
compared across critical socioeconomic characteristics supplied from the Census 
Bureau, with the four states selected having an higher percent of minority 
populations, a higher percent of residents living without health insurance coverage, 
and a higher percent of residents living in poverty. Social descriptors of the four 
states are detailed in Appendix A. Additionally, each of the four states had high 
cervical cancer incidence and mortality rates. In 2003, states were categorized into 
four categories based on cervical cancer incidence and mortality rates. Texas and 
Louisiana belonged to the group of states with the second highest rates and North 
Carolina and New Mexico fell into the third highest category (U.S. Cancer Statistics 
Working Group, 2006). The four states included populations with a higher percent of 
racial/ethnic groups who are at higher risk for cervical cancer. Further, states were 
selected based on the accessibility of providers’ contact information. Based on 
information gathered during a small content validity study (McCave, 2007a) in which 
local providers interviewed provided potential avenues to obtain the lists of providers 
and from continued investigation, a list of primary care providers was obtained in 
each of the states through the boards of medicine and nursing, all of which had 
updated lists as of 2007 of licensed physicians and nurses available for purchase.  
An Excel database for type of provider within each state was created for a 
mailing list. The entire sample was 1500 in total, with 375 providers from each state. 
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The sample size was first based on a power analysis (Cohen, 1992) using Sample G 
Power Software and the following estimates: 1) 95 % power; 2) .01 alpha level; 3) .15 
effect size (medium effect); and 4) four predictors. The alpha level was set at .01 
rather than .05 for two main reasons. According to Cohen (1988), typically the power 
value is set at .80, which allows a .05 probability of a Type I error occurring and a .20 
probability of a Type II error occurring.  The premise is that having a Type 1 error is 
four times more serious than experiencing a Type II error. It was decided that the 
power value would be set to .95 instead of .80 in this study to increase the chance to 
find a significant relationship. In conjunction, it was then determined that the alpha 
level should be set at a stricter level (.01) in order to reduce the probability of 
incorrectly rejecting a true null hypothesis. Second, since the measure was not an 
established index with test-retest reliability or criterion validity, the conservative 
alpha level was used to decrease the chance of Type I error, which could occur from 
measurement error.   
This yielded a minimum final sample size requirement of 169. Further, a 
minimum response rate of 15% was expected, given that response rates for survey 
research varied widely, and the literature on surveying health providers about the 
HPV vaccine ranged from 15% to 50%. While having a total sample size of 1130 
would produce the 169 final sample requirement if 15% was obtained, it was 
estimated that by using a larger total sample of 1500 with a 15% response rate, 
producing a final sample size of 225, the sample would be well above the necessary 
169 cases in order to achieve 95% power. Additionally, the literature indicated a need 
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for studies with larger samples, as a majority of the studies included smaller final 
samples (N < 100), thus limiting generalizability. Also, it was decided that a sample 
size of 1500 would allow potential for within-state and across state comparisons. 
Lastly, the financial resources were considered as it applied to costs associated with 
mailings. While it was initially anticipated that the response rate would be above 
15%, after the end of data collection, there were 227 completed surveys, resulting in a 
15% response rate, which secured the necessary power to reduce Type II Error, thus 
giving confidence to the findings.  
A proportionate stratified random sample (Engel & Schutt, 2005) by type of 
health provider of possible participants was derived to determine the sample (see 
Appendix B). For example, in Louisiana, the entire population of health providers 
obtained through the medical and nursing boards totaled 3,586 individuals. The list 
was comprised of mostly of nurse practitioners (1339 providers, 37%), then family 
physicians (938 providers, 26%), followed by pediatricians (734 providers, 21%), 
with gynecologists and physicians assistants making up the smallest portion of the 
sample (296 and 279 providers respectively, 8% for each).  These groups were then 
proportionally sampled, to be representative of all health providers in the state. 
Continuing with the example of Louisiana, this resulted in 138 nurse practitioners 
randomly selected, 98 family physicians, 79 pediatricians, and 30 providers for both 
gynecologists and physicians assistants.  
It was estimated that within the samples chosen for each type of provider, 
there would be 30% who would not fit into the “target population” of directly 
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working with girls ages 9-12 or 13-17. This estimation was derived from two pieces 
of information. First, there was a range of specificity associated with each state 
provider list; for example, some nursing boards offered only contact and licensure 
information, whereas some medical boards provided quite detailed information about 
each provider (such as specialization of practice). Second, from a small pilot study 
carried out in April 2008, in which 10 providers were randomly selected to answer 
key questions about the mail survey (see Appendix C), 30% of selected participants 
either indicated that they were non-target population providers (e.g., worked in sports 
medicine or neonatal unit) or did not respond at all, with the latter category 
considered potentially non-target as well.  
Consequently, an additional random sample was generated to serve as a 
contingency sample for that 30% of non-target providers. Those providers were only 
used to replace those participants who indicated that they were not-target providers, 
or when a mailing was sent back as “return to sender”. The contingency sample was 
not drawn upon for those who were able to receive the survey and chose not to 
respond. Following the example of Louisiana, an additional 114 providers were 
designated as the contingency sample, 42 of those were NPs, 30 were family 
physicians, 24 were pediatricians, and 9 were selected for both gynecologists and 
PAs.  Once the designated 30% contingency sample was used up for a particular 
category, no other contingency providers were sent mailings from that sub-sample. 
For example, this occurred with New Mexico Physician Assistants, from which all the 
contingency sample were drawn; subsequently, when additional mailings were 
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returned within this sample as un-usable there were no more mailings sent out as 
replacements (such as drawing from the New Mexico pediatrician contingency 
sample).  
In order to track respondents, a unique identifier was given to each potential 
participant. This unique identifier was printed on the outside of the return envelope 
and was not listed anywhere on the actual survey, to ensure anonymity. When surveys 
were returned, the unique identifiers allowed this researcher to document whether it 
was a completed survey, a “return to sender”, or a “non-target population” 
respondent.  
An invitation letter (see Appendix D) was sent out during the first week in 
May 2007 to 1500 providers, 375 providers from each state. The letter invited 
providers to access an online site that would allow them to complete the survey 
online, using Ultimate Survey (a program supported by the University of Kansas 
School of Social Welfare), with the option to request the survey via mail, email, or 
fax, or to indicate that the provider was not working directly with either 9-12 or 13-17 
year olds. The web survey, which was password-protected, included the informed 
consent, along with the same version of the survey. 
The invitation letter stated the purpose of the study and indicated that 
completing the survey demonstrated informed consent. The invitation letter clearly 
stated that the study was independent of any support from Merck™, the 
pharmaceutical company responsible for Gardasil ™. The mailing also included a 
signed letter of support (see Appendix E) from a local gynecologist and nurse 
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practitioner, both of whom were involved in one of the clinical trials with Gardasil 
™. This method was suggested by local providers during the content validity study. It 
was also supported by Vangeest, Johnson, and Welch (2007), who in their review of 
the literature on methods to increase response rates with physicians, recommended 
including endorsements by professional associations.  
As an incentive for returning a completed survey, this researcher donated $1 
for each completed survey to The American Cancer Society (http://www.cancer.org), 
and emphasized the possibility of a sizeable donation if a large number of surveys 
returned. Participants were provided with a free executive summary of the findings of 
the study as further incentive and access to an informational website created by this 
student. 
Within the first week of survey responses, it became apparent that there were 
technical difficulties with the Ultimate Survey program software. From close 
monitoring of the online access site and online survey, as well as contact from 
providers to this researcher via email and phone, it was evident that providers were 
attempting to complete the survey but were unable to do so for technical reasons (e.g., 
“getting ‘kicked off’ the server”). During this first week, the online access site 
received 81 “hits” but only 32 participants completed online surveys. Records 
indicated that some participants tried to access the online survey more than one time 
but were unable to do so. There were several participants who were able to request 
the survey by mail, fax, or email or indicate that they were not the target population; 
some respondents however, were unsuccessful in this process due to an additional 
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technical glitch in which the software did not provide the appropriate branching 
option designated for each unique request (e.g., link respondent to follow-up 
questions for requesting survey by fax). It was also discovered that there was no way 
to “track” the respondents, since the IP addresses between the initial access website 
and the actual online survey did not always correspond. This problem had not been 
anticipated, and in fact, information had been provided that tracking respondents in 
this way would not be an issue.  
Given that the technical support staff could not determine the cause of these 
software problems, the web-based aspect of the survey was taken off-line and the 
mail survey became the main method of dissemination. Since the literature on web-
based surveys indicated that typically participants respond within the first week of 
receiving the invitation, this was considered the first round of data collection.  
Between May 19th and the 28th, a follow-up reminder letter and mailing of the 
actual survey was sent to each of the non-respondents, with a stamped, return 
envelope (see Appendix F and G for follow-up letter and mail survey). Additionally, 
as mailings came back “return to sender” (i.e., undeliverable) or came back with a 
note that the provider was not a “target population” respondent, a corresponding 
provider within the pool of randomly selected contingency providers was mailed an 
introduction letter (see Appendix H) along with the actual mail survey, and stamped, 
return envelope. Within the first two weeks, 70 envelopes had come back “return to 
sender”. As mailings were returned completed, incomplete (i.e., survey missing 
answers on several primary variables or missing entire page(s) of survey), or return to 
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sender, this information was tracked using an Excel Database of all potential 
respondents and mail dates. An “ebb and flow” existed such that mailings would 
arrive sporadically as return to sender or incomplete due to not being a “target 
population” provider, and new contingency providers would be selected from the 
corresponding sub-sample and an initial mailing would be sent out. First follow-up 
mailings for these individuals occurred three to four weeks after the first mailing was 
sent. This process continued through the summer months and concluded during the 
month of October, 2008. Reminders were not sent to participants during the data 
collection period due to budgetary constraints.  
Types and Sources of Data to be Gathered 
Given that there was not a measure already established that addressed the 
specific research questions, a new survey was developed for this particular study 
(McCave, 2007a). A small face validity study was conducted with five healthcare 
providers to determine the feasibility of the instrument. It was revised to incorporate 
the specific feedback of the wording and presentation of the questions, as well as any 
salient questions that were not addressed. This small study received IRB approval 
through the University of Kansas.  
The survey took approximately five minutes to complete, and asked 
professional and demographic information first, followed by questions regarding 
vaccination of female patients aged 9-12 and 13-17. Additional questions followed, 
addressing the HPV vaccination actions, perceived barriers and supports for both age 
groups. The six main variables of interest were:  
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1) HPV vaccination actions: nominally defined as any actions taken related to 
the vaccination of female patients aged 9-12 and 13-17, with initial ratio-level 
questions about actual vaccination rates for each age group and then questions about a 
range of actions that were indirect in nature (e.g., referring patient to a specialist or 
requesting an increased vaccine supply), which were nominal in level. 
2) Health Care Access Indicators reported by each provider: nominally 
defined as a set of demographic and economic characteristics of providers and their 
patients. There are seven variables belonging to this cluster. They include: 1)  percent 
of providers’ minority patients ages 9-17; 2) percent of private insurance patients ages 
9-17; 3) Ethnicity/Race of healthcare provider; 4) type of practice; 5) percent of 
providers’ patients vaccinated using private insurance to pay for vaccine; 6) percent 
of providers’ patients vaccinated using public insurance or funding to pay for vaccine; 
and 7) practice registered as a VFC approved site .These characteristics were made up 
of both nominal and ratio variables.  
3) Level of state policy initiative: an ordinal variable defined as a) passed state 
legislation that requires insurance companies to provider coverage of the HPV 
vaccine for girls ages 9-14 (“health insurance” in New Mexico); b) passed state 
legislation that requires HPV vaccine educational materials distributed to parents of 
fifth through twelfth graders (“educational fact sheets to parents” in North Carolina); 
c) passed state legislation that requires education to the public in English and Spanish 
and a ban against future vaccine mandate for school enrollment (“bilingual 
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education—not appropriated and ban on mandate” in Texas) or d) no state policy 
initiative (“no policy initiative” in Louisiana). 
4) Job title of the health provider:  nominally defined as health provider who 
is likely to give the vaccine to girls ages 9 to 17 and was a nominal variable with five 
categories: a) pediatrician, b) family physician, c) nurse practitioner, d) gynecologist, 
and e) physician assistant. 
5) Vaccination barriers: nominally defined as any process, attitude, belief, or 
object that limits the ability to participate in actions that lead to vaccination. Barriers 
were separated into five personal barriers and seven professional barriers, and a sum 
of these barriers indicated was used as a ratio variable that had two subscores and an 
overall score. Personal barriers included limited personal knowledge on HPV, 
personal discomfort with the topic, concerns about Merck’s products, limited personal 
knowledge about the state initiative, and concerns about the media’s presentation of 
the vaccine. Professional barriers included concerns about safety, effectiveness, 
medical purview, reduction in future Pap screenings, financial burdens, the state 
policy initiative, and patients’ negative perceptions of the vaccine. 
6) Vaccination supports: nominally defined as any process or object that 
promotes the ability to participate in actions that lead to vaccination. Similarly, 
supports were separated into four personal and seven professional supports, which 
also produced a summary ratio variable that had two subscores and an overall score. 
Personal supports included personal comfort with the topic, a positive personal 
experience with the vaccine, belief that the vaccine saves lives, and media exposure. 
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Professional supports included additional information on HPV and how to talk with 
parents, and financial resources available, as well as a forum with other providers, 
state policy initiative, and adherence to professional association’s recommendations.  
Additional survey items included questions on who typically initiates the 
conversation about HPV vaccination (i.e., provider, patient, another provider, or 
parent), amount spent by provider on the HPV vaccine, and protective financial 
measures related to the vaccine. 
Efforts were made to reduce data entry error by doing manual data re-
checking of every paper survey response. Any missed errors were discovered during 
the preliminary descriptive statistics analyses. Surveys initially completed with the 
Ultimate Survey software were imported directly into an Excel database and were 
double checked as well. Missing data was checked for each survey. When entering 
the data, the researcher made decisions about “rounding” that once made, were 
consistent throughout the data entry process. Such decisions included the following: 
1) If a range was provided for the hours of week or the percent vaccinated, the mean 
was taken and rounded to the nearest whole number (e.g., “5-7” hrs a week was 
reported as 6; “50 to 75%” was reported as 63%); and 2) if a plus or minus label was 
attached to any of the values, such as the years spent practicing as a clinician or 
percent of clients who are minority patients, the consecutive whole number was 
reported (e.g., “40+” years was reported as 41 or “less than 50%” was reported as 
49%). Also, given that so few individuals reported any new items on the “other” 
category for either barriers or supports, they were added to the open ended comments 
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recorded as “most impactful barriers” and “most impactful supports”. A code list was 
developed for each of the variables and all the data was coded accordingly. Each of 
the overall scores and subscores were manually calculated and entered into the Excel 
Database. Once all data was recorded, an SPSS database was created.  
Validity and Reliability of Measure 
Efforts were taken to increase the validity of the questions on the survey used 
in this study. First, face validity was achieved through both pre-testing and pilot 
testing the survey with healthcare providers. Questions on the survey were clearly 
related to the concepts being measured (e.g., vaccination was measured by questions 
asking percent vaccinated). Those included in the pre-test and pilot test confirmed 
that the survey “on its face” was valid (Engel & Schutt, 2005, pg. 89). Second, 
content validity can be achieved through the solicitation of feedback by experts as 
well as drawing from the literature to ensure the concepts meaning are fully covered 
by the measure. Through the pre-test and pilot test as well as an extensive review of 
the literature, this researcher attempted to include all questions that were relevant to 
HPV vaccination and the barriers and supports associated with vaccination. Neither 
criterion or construct validity were established for this study, however it may be 
reasonable that both may be tested in the future.  
In regards to reliability, given that there were multiple items measured for the 
concepts of vaccination barriers, vaccination supports, and vaccination actions, it was 
important to assess the internal consistency of these items. Using Cronbach’s alpha 
coefficient as a measure of internal reliability, where alpha levels of .85 or .90 are 
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considered very high (Engel & Schutt, 2005), the tests confirmed that there were 
sufficient reliability within the three sets of items that each produced summary scores 
(namely HPV vaccination barriers, supports, and actions). First the internal 
consistency levels for the items asking about HPV vaccination barriers for girls ages 
9-12 and 13-17 were α = .693 and α = .670, respectively. Second, the internal 
consistency levels for the items asking about HPV vaccination supports for girls ages 
9-12 and 13-17 were α = .665 and α = .684, respectively. Lastly, the internal 
consistency levels for the items asking about HPV vaccination actions for girls ages 
9-12 and 13-17 were α = .471 and α = .409, respectively.  While these latter scores 
were not as high, it should be noted that the overall score for actions was not utilized 
in a multivariate analysis. For each of the items that made up the barriers and supports 
scales for both age groups, it was clear alpha was not increased significantly by 
eliminating any one item. Consequently, no additional analyses were conducted using 
modified barriers or supports scores.  
Methodological Problems Encountered 
Note that this study used a self-administered questionnaire, which can be 
considered a direct measure (Engel & Schutt, 2005); however, a limitation with this 
approach is that the survey queried attitudes rather than observing behaviors and 
gathering those data directly. Such forms of measurement may have affected the 
responses through social desirability, and as such, may have reduced the validity and 
reliability of the answers. It is possible that primary care providers may have provided 
answers that they believe were expected of them as medical professionals, rather than 
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accurately reporting their personal barriers.  However, the content validity study 
(McCave, 2007a), aimed at eliminating leading questions within the questionnaire, 
along with the anonymity afforded to the respondent, may have lessened these effects. 
Further, responses from the survey suggest that participants were willing to share 
their personal barriers, thus reducing the social desirability bias.  
An additional limitation was that there was not triangulation of the data 
through use of multiple sources of measurement (Engle & Schutt, 2005). Moreover, 
because this was a new questionnaire, it is possible that there was systematic error as 
a result of the measurement error; however, it was not likely known apriori because 
of the lack of prior use of the questionnaire, thus making it difficult to predict the 
nature of the systematic error.  
Specific Statistical Analyses Used 
Once the data was collected, the first step was to calculate descriptive 
statistics on the main variables mentioned above.  The five research questions were 
answered through the following statistical methods.  
 Research Question A:  Four paired-samples t-tests were conducted to 
understand whether providers' HPV vaccination rates were higher for girls aged 13-17 
compared with girls aged 9-12 within each state. 
Research Question B: Two univariate ANOVA tests were used to determine 
whether HPV vaccination rates for girls ages 9-12 and girls 13-17 differed 
significantly when considering the type of state policy.  
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Research Question C: Two multiple regression analyses were conducted to 
determine the whether indicators of health care access, namely insurance status and 
racial background, were predictive of higher HPV vaccination rates for each age 
group. Predictor variables included the percent of minority patients, percent of 
patients using private insurance, percent of patients using private or public insurance 
to pay for the vaccine, with the percent vaccinated in each age group as the two 
dependent variables.  
Research Question D:  Descriptive statistics were utilized to answer what 
healthcare providers identified as the most common barriers, supports, and HPV 
vaccination actions. The open ended questions that indicated which barriers and 
supports were reported as having the most impact on HPV vaccination actions were 
coded with Atlas software to allow a rank ordering of most influential barriers and 
supports. 
Research Question E: Prior to running the necessary multiple regression 
models to determine which combination of predictors was most predictive of 
healthcare providers’ HPV vaccinations of girls aged 9-12  and girls aged 13-17, two 
Spearman correlation matrixes (one for each age group) including the four 
independent variables (i.e., type of provider, state policy, overall barriers scores, and 
overall supports scores) were conducted for each age group to determine if 
multicollinearity was a problem. Only two of the independent variables were 
significantly correlated, namely type of provider with overall supports scores for both 
age groups. Given that multicollinearity was not found to be a preliminary issue, the 
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two multiple regression analyses were then conducted. From there tolerance statistics 
further confirmed that multicollinearity was not a problem.  
Steps Taken to Protect Human Subjects 
In order to protect participants, human subjects approval was sought through 
the University of Kansas Institutional Review Board (IRB). The IRB was completed 
prior to the start of the study. The subjects of this study were not health consumers, 
but adult healthcare professionals. There were no children included in this study, and 
women and minorities were included to the fullest extent possible. Increased 
representation of women and minorities was enhanced by including nurse 
practitioners in the sample and selecting states with larger percentages of minority 
groups.  
There were not any expected risks for respondents beyond what was expected 
from daily professional life. Benefits for respondents included access to a summary of 
results from this study, as well an online resource page on information related to the 
HPV vaccine. Indirect benefits included contributing to the advancement of public 
health knowledge and research as well as indirectly contributing to the American 
Cancer Society, as $1 was donated for each survey returned. Steps were taken to 
ensure anonymity and confidentiality. This researcher did not ask social security 
information, as respondents did not receive any financial compensation. Completed 
mailed surveys were separated from their return envelopes, which contained the 
unique identifiers assigned to each potential participant. This allowed for the tracking 
of respondents and non-respondents while keeping participants’ answers anonymous. 
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Returned mail surveys were kept in a locked cabinet as were the returned envelopes 
containing the unique identifiers. Excel databases with the lists of providers selected 
for sampling were saved on a password protected computer. Those initial participants 
who completed the survey online were able to maintain anonymity, as the online 
consent form and the actual surveys answers were separated, with the survey 
password protected and only this doctoral student had primary access to the data that 
arrived. This researcher agreed to keep all individual information, such as 
participants’ names, confidential. Written informed consent was required of all 
participants; reading the information statement and completing the survey was 
considered informed consent, per the policy of the University of Kansas IRB (D. 
Hann, personal communication, November 14, 2007). Monitoring of this study by 
this student’s dissertation chair and committee provided appropriate oversight of 




















Chapter 5: Results 
 
 This chapter discusses the results from the statistical analyses used to answer 
the research questions. Prior to discussing each research question, statistics are shared 
that highlight how the data collection process led to the final sample as well as 
characteristics of the sample by state and type of provider. Following this is a brief 
presentation of the normality of data on the two dependent variables, namely 
vaccination of girls in each age group. This is followed by an account of distributions 
and statistics for each research question and the independent variables included.  
Sample Derivation  
In order to determine if there were any patterns of non-response, the data 
collection response and non-response process was examined closely. Table 1 
highlights this process, with the first column indicating the number of respondents 
likely reached (i.e., number total participants minus the number of returned to sender 
and non-target population respondents). The second and third column indicate those 
respondents who were not reached due to relocation (i.e., returned to sender) or being 
reached but indicating that the provider did not work with the population of interest. 
The fourth column shows the number of respondents for each type of provider within 
each state who were selected as contingency participants. This is followed by the 
number of surveys completed within each state by type of provider and the associated 
response rate.  
Table 1 reveals that Texas had the highest number of respondents who 
indicated that they were “non-target population” providers. New Mexico came in just 
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under Texas in this category but also had by the far the highest number of mailings 
returned to sender, which resulted in New Mexico having using the most contingency 
participants in all four states. The fewest contingency participants were utilized in 
North Carolina, where the number of respondents who identified as “non-target 
population” was the lowest and the number of mailings returned to sender was also on 
the lower end. In three of the four states, Nurse Practitioners made up the largest 
proportion of respondents who indicated that they were “non-target population” 
providers and also typically responded the most frequently. In contrast to this, 
Physician Assistants typically were the least likely to respond. Physicians Assistants 
were a unique group, in that they were the only ones who did not have any 
respondents for an entire state, namely Louisiana. This leads to questions as to 
whether Physicians Assistants are in any way different from those from the other 




















Table 1 Response and Non-Response During Data Collection by State and Type of 
Provider  
* Indicates contingency sample was completely utilized, thus preventing additional 
contingency mailings for Physician Assistants in New Mexico.  
Variable Total #  Sent 

















NM (Total) 366 33 60 85 71 19.4%
FP 96 7 17 24 16 16.7
GYN 33 1 3 4 6 18.2
PED 56 3 10 13 11 16.6
NP 127 16 10 26 32 25.2
PA 54 6 20 18* 6 11.1
LA (Total) 375 35 24 59 50 13.3
FP 100 3 9 12 12 12.0
GYN 30 1 3 4 5 16.7
PED 78 3 9 12 12 15.4
NP 137 25 1 26 21 15.3
PA 30 3 2 5 0 0.0
NC (Total) 383 13 19 32 60 15.7
FP 143 5 6 11 16 11.1
GYN 66 1 5 6 14 21.2
PED 83 4 2 6 13 15.7
NP 43 2 5 7 9 20.9
PA 48 1 1 2 8 16.7
TX (Total) 366 24 19 40 44 12.0
FP 101 1 5 6 12 9.9
GYN 45 1 1 22 6 13.3
PED 58 4 2 6 7 12.1
NP 103 11 1 12 14 13.6
PA 59 9 8 14* 5 8.5
Combined 
total 1490 105 122 216 227** 15.2




Characteristics of the Sample 
From the 1490 providers likely to have received the survey, 227 individuals 
responded from the four states, with most responses from New Mexico, then North 
Carolina, Louisiana, followed by Texas (see Table 2). The overall response rate was 
15.2%, which has been typical for the lower end of the survey response rates found 
with this population (Kellerman & Herold, 2001). Among the 227 respondents, most 
were Nurse Practitioners, followed by Family Physicians, Pediatricians, 
Gynecologists, and lastly Physician’s Assistants. A proportionate stratified sample 
was selected by type of health provider, such that the proportion of each type of 
provider within each state was sampled (refer to Appendix A). The selected 
proportions for the sample were then compared with the actual proportional 























Average Response Rates and Standard Deviations by State and Type of Provider  











Variable Total # Responded  
State 
New Mexico 73 (32.2%) 
North Carolina 60 (26.4%) 
Louisiana 50 (22.0%) 
Texas 44 (19.4%) 
Total 227 (100.0%) 
Type of Provider 
Nurse Practitioners 76 (33.5%) 
Family Physicians 56 (24.7%) 
Pediatricians 43 (18.9%) 
Gynecologists 31 (13.7%) 
Physician Assistants 19 (8.4%) 
Missing 2 (0.8%) 
























Proportionate Stratified Sampling by Provider Type with Proportional 
Representation in Final Sample 
 
Variable Proportion Sampled  
Proportional 
Representation  
in Final Sample 
New Mexico   
Physician assistants 17.2% (64)   8.5% (6) 
Pediatricians 15.2% (56) 15.5% (11) 
Gynecologists   8.9% (34)   8.5% (6) 
Family physicians 24.7% (94) 22.5% (16) 
Nurse practitioners 34.0% (127) 45.1% (32) 
Total 100.0% (375) 100.0% (71) 
Texas   
Physician assistants 16.2% (60) 11.4% (5) 
Pediatricians 14.5% (56) 15.9% (7) 
Gynecologists 11.6% (45) 13.6% (6) 
Family physicians 30.2% (113) 27.3% (12) 
Nurse practitioners 27.5% (101) 31.8% (14) 
Total 100.0% (375) 100.0% (44) 
Louisiana   
Physician assistants   7.7% (30)   0.0% (0) 
Pediatricians 20.5% (79) 24.0% (12) 
Gynecologists   8.6% (30) 10.0% (5) 
Family physicians 26.2% (98) 24.0% (12) 
Nurse practitioners 37.3% (138) 42.0% (21) 
Total 100.0% (375) 100.0% (50) 
North Carolina   
Physician assistants 12.1% (45) 13.3% (8) 
Pediatricians 21.1% (79) 21.7% (13) 
Gynecologists 16.9% (64) 23.3% (14) 
Family physicians 39.2% (146) 26.7% (16) 
Nurse practitioners 10.7% (41) 15.0% (9) 




















There was a pattern in the proportional representation of each type of provider 
when compared with the proportion originally sampled. In all four states, nurse 
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practitioners made up a larger proportion of the collected sample than was selected 
based on the proportions of the sampling frame. In three of the four states, 
pediatricians and gynecologists responded very closely to their proportions selected in 
each state. In comparison, physician assistants were represented in a smaller 
proportion in three out of the four states. This highlights that nurse practitioners are 
more likely to be overrepresented in the final sample and physician assistants are 
likely to be underrepresented.  
Females made up a higher proportion of the sample as compared to males 
(67% vs. 33%, respectively). The range of years spent practicing as a clinician 
spanned 1 year to 44 years, with a median of 12 years. Age of clinician ranged from 
25 years old to 71 years old, with a median of 48 years of age.  
Characteristics of Dependent Variables 
Given that the percent vaccinated for each age group was the dependent 
variable for four of the five research questions, it is important to highlight the 
distribution of the data prior to discussing the results for these four research 
questions. It should be noted that there was positive skewing on the variable asking 
percent of girls 9-12 vaccinated, with a majority of providers reporting that they had 
not vaccinated any girls in this age group (see Figure 1). Additionally, there were 23 
missing cases for this variable. In order to determine if the missing values were 
influencing the results, the analyses were re-run with the means of this variable for 
each state. It was concluded that the results did not differ greatly and no additional 
significant differences were found.  
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Histogram of Dependent Variable: Percent Girls 9-12 Vaccinated 
The second dependent variable, percent of girls 13-17 vaccinated, also did not have a 
normal distribution, as there was a wide range of responses by providers (see Figure 
2). While the most frequent response was not vaccinating at all, providers also 
frequently reported vaccinating 50% or more of their patients. Given this information 
about both dependent variables, it is likely that the distribution of responses may 
influence the results, however, the statistical tests utilized in the analysis are typically 




























Histogram of Dependent Variable: Percent Girls 13-17 Vaccinated 
 
Bivariate and Multivariate Statistics 
 This section of the results chapter reviews the statistical findings for five 
research questions examined in this study. Issues of normality and distribution are 
mentioned when the relevant variables were utilized in the analysis. The importance 




Research Question A  
The first research question asked whether providers' HPV vaccination rates 
were higher for girls aged 13 to 17 compared with girls aged 9 to 12 in each state. 
The hypothesis was that vaccination rates would be significantly higher for girls aged 
13-17 than for girls aged 9-12 in all four states. Four paired-samples t-tests were 
conducted to determine whether providers’ HPV vaccination rates were significantly 
higher for girls aged 13-17 compared with girls aged 9-12 within each state (see 
Table 4 for statistical results, where p ≤ .01 is significant). The hypothesis was 
confirmed for three of the four states. The results indicated that in New Mexico, 
Texas, and North Carolina, the mean vaccination rate for girls 13-17 was significantly 
greater than the mean vaccination rate for girls 9-12. Lastly, the results indicated that 
there was not a significant difference in Louisiana between the mean vaccination rate 
for girls in the two age groups. Notably, the standard deviations statistics were the 
highest in this state, indicating that there was the highest variability of responses in 
this particular state.  
Table 4 
T-tests of Vaccination Rates for Both Age Groups within each State 
* p < .01 
Variable M %  13-17 Vaccinated (SD) 
M %  9-12 Vaccinated 
(SD) 
Statistical Results for Question A: 
Influence of Age on Vaccination 
NC    57.1% (32.14)    33.7% (32.09) t(54) = -6.09, p = .000* 
LA 44.1 (33.61) 35.5 (34.01)            t(45) = -2.34, p = .024 
NM 40.9 (30.66) 25.6 (29.78) t(62) = -4.78, p = .000* 
TX 35.9 (29.97) 24.7 (25.91) t(39) = -3.73, p = .001* 
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There are two variables that are not included in this analysis that are 
potentially important to consider. The survey asked providers to report the number of 
hours worked each week with girls 9-12 and then again for girls 13-17. Notably, 
statistics indicate that the distribution of data on both of these variables were 
positively skewed, such the average number of hours worked directly each week with 
girls in both age groups was fewer than eleven hours. Providers reported working 
more frequently with girls 13-17 each week (M = 10.90, SD = 11.97) than girls 9-12 
(M = 8.70, SD = 12.53). For the lower age group, 8.8% of providers indicated that 
they did not work at all with girls 9-12. For these individuals, they were only included 
in the final sample if they did work with girls in the older age group. Consequently, it 
could be that the vaccination rates for girls 13-17 may be higher due to providers 
treating a higher number of girls each week in this age group. Still, this finding is 
consistent with the literature in revealing that health providers are vaccinating girls in 
the older age group at higher rates then their younger counterparts. This is important 
given the CDC’s recommendation that 11 and 12 year old girls are the target age 
group, which will be discussed in more depth in the next chapter.  
Research Question B 
This research question asked whether provider HPV vaccination rates for each 
age group would differ in states with varying policy initiatives. The hypothesis was 
that vaccination rates would differ significantly for both age groups depending on the 
state policy initiative, with New Mexico (with the mandate for health insurance 
coverage for girls 9-14) having the highest vaccination rates for both ages.  
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Overall, North Carolina had the highest vaccination of girls in both age 
groups, followed by Louisiana, New Mexico, and lastly Texas (see Table 5). It should 
be noted that in terms of the distribution of the data on the independent variable, state 
policy, there was a slight over-representation by New Mexico and under-
representation by Texas, however the data was not skewed.  
Table 5 










Variable Mean % 
Vaccinated, 
All Ages 
Mean %  13-17 
Vaccinated 
(SD) 





55.8% (32.47)  
n = 59 
32.7% (32.09) 




n = 50 
35.5 (34.01) 




n = 67 
25.6 (29.78) 




n = 43 
24.7 (25.91) 
n = 46 
Total  37.0 44.3 (219) 29.6 (204) 
Two ANOVA tests were completed to determine the effect of state policy 
initiative on mean percent of vaccination for each age group. The hypothesis that 
New Mexico would have significantly higher vaccination rates than the other three 
states was not supported, as New Mexico had lower vaccination rates for both age 
groups than both North Carolina and Louisiana.  Results from the first ANOVA 
indicated that vaccination rates for 9-12 year old girls did not differ significantly 
when state policy initiative was considered (F(3, 200) = 1.461, p = .226). The second 
ANOVA test did show a significant difference for mean percent vaccination rates for 
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girls 13-17 when considering type of state policy (F(3, 215) = 3.987, p = .009). Mean 
differences for each age group by type of state policy can be found in Table 6. In 
considering post-hoc tests, homogeneity of variance was assumed after Levene’s test 
was not significant, thus Tukey HSD was used to examine multiple comparisons. 
There were no significant differences found in the post-hoc tests that compared two 
states at a time.  
Table 6 
ANOVA tests of Vaccination Rates for Both Age Groups Across States 
 
*p ≤ .01 
Variable Mean % 13-17 Vaccinated 
(SD) 
Mean % 9-12 Vaccinated 
(SD) 
Statistical results for Question B: 
Influence of state policy on 
vaccination  
F(3, 215) = 3.987, p = .009* F(3, 200) = 1.461, p = .226 
NC(a) 
 55.8 (32.47) 32.7 (32.09) 
LA(b) 
 45.0 (33.49) 35.5 (34.01) 
NM(c) 
 39.6 (30.56) 25.6 (29.78) 
TX(d) 
36.6 (29.04) 24.7 (25.91) 
Total 
44.6 (32.14) 29.6 (30.83) 
(a) North Carolina legislation requires Health Dept. to provide educational fact sheets to 
parents of all children in grades 5-12 starting in 2007-08 school year 
(b) Louisiana currently has no legislation passed related to HPV vaccination 
(c) New Mexico legislation passed mandate for HPV vaccination for school enrollment but 
was overturned by Governor, now requires health insurance coverage for New Mexico girls 
ages 9-14 vaccinated 
(d) Texas legislation vetoed Executive Order by Governor to mandate HPV vaccine for 
school enrollment, passed a ban against future mandates, and also requires education to the 
public from Dept. of Health for English and Spanish Speaking populations (the latter of 
which was not appropriated) 
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The findings from these analyses highlight the difficulty in measuring and 
studying the effects of state-wide social policy. While New Mexico was the only state 
examined that offered a financial incentive for the HPV vaccine (i.e., health insurance 
coverage for the vaccine), which has been repeatedly discussed as a major support in 
the literature, it was not reflected in vaccination rates for either age group. This is also 
confirmed by the descriptive statistics, which show that providers in New Mexico 
reported by far the lowest percent of patients using private insurance to pay for the 
vaccine. This raises the question as to why the initiative is not being utilized, perhaps 
because of lack of education to providers and patients about the state policy initiative. 
Another possibility may be that the veto by the Governor to counteract the vaccine 
mandate for school enrollment is having a negative influence on provider and patient 
vaccination behaviors. This will be discussed further in the next chapter.  
Research Question C 
This research question asked the nature of the relationship between indicators 
of health care access and vaccination rates in both age groups. The hypothesis was 
that using private insurance and belonging to a non-minority background would be 
predictive of higher HPV vaccination rates in both age groups. Two multiple 
regression analyses were conducted to predict vaccination rates for each age group 
using health access indicators as predictor variables. The four predictor variables 
included: 1) percent of patients aged 9-17 who are minorities, 2) percent of patients 
aged 9-17 using private insurance, 3) percent of providers’ patients using private 
insurance to pay for the HPV vaccine, and 4) percent of providers’ patients using 
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public insurance or monies to pay for the vaccine. The percent vaccinated in each age 
group served as the two dependent variables.   
In terms of the normality of the independent variables, histograms revealed 
that both percent of patients who used private insurance to pay for the HPV vaccine 
and percent of patients who used public monies to pay for the vaccine had high 
numbers of cases on either end of the distribution (100% and 0%). This reflected that 
patients typically use only private or only public insurance, rather than a combination 
of both forms of insurance.  The other two independent variables, percent of patients 
aged 9-17 who are minorities and percent of patients aged 9-17 who are private 
insurance patients, both had relatively normal distributions. Providers reported on 
average that half of their patients aged 9-17 were patients from minority backgrounds 
(Table 7). Similarly, providers reported nearly a 50/50 split between the rates of using 
private versus public insurance to pay for the vaccine, with a slightly larger 
proportion of their patients utilizing public insurance to pay for the vaccine. This 
makes sense, given that less than half of providers’ patients aged 9-17 were identified 
as private insurance patients. This suggests that patients pay for vaccinations in the 
same manner that they pay for other health services.   
Table 7 
Averages and Standard Deviations on Four Predictors Variables 
Variable Mean (SD) 
Percent of providers’ patients aged 9-17 who are minorities 50.4% (30.07) 
Percent of providers’ patients aged 9-17 who are private insurance patients 43.8 (34.18) 
Percent of patients using private insurance to pay for vaccine 44.4 (39.94) 
Percent of patients using public insurance or monies to pay for vaccine 51.76 (40.71) 
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In the first multiple regression analysis, the linear combination of health 
indicators was not significantly related to HPV vaccination rates for girls 9-12, F(4, 
168) = 3.01, p = .02, thus indicating that the model was not a good fit for predicting 
the dependent variable.  
In the second multiple regression analysis for girls 13-17, the model was 
significant, F(4, 181) = 4.77, p ≤ .01, with 9.5 percent of the variance in the 
dependent variable explained by the model. Two of the four health care access 
indicators that were used as predictor variables were individually significant in the 
model (See Table 8). These predictors included the percent of providers’ patients who 
used private insurance to pay for the HPV vaccine (t(184) = 3.34, p = .001) and those 
who used public insurance or funding to pay for the vaccine (t(184) = 2.81, p = .006). 
The results suggest that providers vaccinate girls ages 13-17 at a higher rate 
when a greater proportion of their patients are using private insurance to pay for the 
HPV vaccine, as well as using public insurance or monies. This is contrary to what 
would be expected, given that there was a strong negative bivariate correlation (r = -
.841) between the two independent variables. However, there was only a small 
positive relationship with using private insurance to pay for the vaccine with 
vaccination rates for girls 13-17 (r = .232), and an even weaker negative relationship 
between using public insurance to pay for the vaccine with the dependent variable 
(r = -.095). This suggests that when you control for the other predictor variables, the 
use of public funding to pay for the vaccine no longer has a negative relationship with 
the dependent variable but rather predicts slightly higher vaccination rates.  
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Table 8 













Predictors B β t 
Percent of patients aged 9-17 private 
insurance .041 .046 .393 
Percent of patients aged 9-17 minority  -.081 -.082 -.919 
Percent of patients vaccinated using 
private insurance to pay for HPV 
vaccine 
.357 .475 3.34* 
Percent of patients vaccinated using 
public insurance/monies to pay for 
HPV vaccine 
.280 .379 2.81* 
* p ≤ .01 
 
These findings suggest that racial background of patients is not a predictor of 
vaccination rates reported by providers, and thus poses the question as to whether it is 
an indicator of health care access in this particular context. Overall, across the four 
states, an average of 50% of providers’ patients were reportedly from minority 
backgrounds. This raises the question whether access to vaccination is less difficult 
than other forms of health care, such as treatment for chronic illnesses. Further, in 
regards to the significance of utilizing private insurance to pay for the vaccine, North 
Carolina had the highest percent of providers reporting their patients used private 
insurance to pay for the vaccine. In connection to that, North Carolina had the highest 
vaccination rates of all four states. This suggests that providers will be more likely to 
vaccinate girls 13-17 if patients are able to access and utilize private insurance. As to 
the finding that using public insurance is predictive of vaccination, it is possible that 
accessibility to free vaccination played a role, as more than 50% of providers (NC = 
57.1%, NM = 80.8%, and LA = 61.2%) in the three states with the highest 
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vaccination rates reported that their clinic or private practice was registered as an 
official VFC site, a service that is targeted towards Medicaid-Eligible patients. Texas 
had the lowest reported vaccination rate and the lowest percent of VFC registered 
providers (45.2%).  
Research Question D 
This research question asked about health providers’ most frequently reported 
barriers, supports, and HPV vaccination actions. The follow-up question asked which 
barriers and supports had the most influence on HPV vaccination rates. Respondents 
were asked to indicate which of the five personal and seven professional HPV 
vaccination barriers they encountered as well as which of the four personal and seven 
professional HPV vaccination supports they had received. Additionally, respondents 
were asked which of the six actions they had participated in related to HPV 
vaccination. Respondents were asked to check all that applied for barriers, supports, 
and actions.  
It was hypothesized that the most common actions would include counseling 
parents on the HPV vaccine and seeking additional information on the HPV vaccine. 
Additionally, the hypothesis for the most common barriers was that financial burden 
and concerns about negative perception of patients about the HPV vaccine would be 
most frequently reported. The most common supports were hypothesized to include 
the personal belief that the HPV vaccine would have a positive impact on women’s 
lives, the state policy initiative, and adherence to professional recommendations 
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Further, it was hypothesized that financial burden would be reported as the most 
influential burden and the policy initiative as the most influential support.  
The distribution on the variables for each age group on the overall barriers 
scores, overall supports scores, overall actions scores as well as the subscores for both 
the personal and professional barriers and supports were relatively normal. There was 
no major skewing found in any of the distributions. Most providers reported three to 
four vaccination activities for both age groups. Providers most typically reported zero 
to two barriers present overall for both age groups, while three to four supports were 
most frequently reported by providers for girls in both age groups.  
Table 9 
Averages and Standard Deviations on Activities, Barriers, and Supports Variables 
 
Variable Mean Score (SD) 
Overall activities score 
       Girls 9-12 
       Girls 13-17 





Overall barriers score 
       Girls 9-12 
       Girls 13-17 





Overall supports score 
       Girls 9-12 
       Girls 13-17 












Results from the descriptive statistics confirmed the hypothesis that the most 
frequently reported HPV vaccination actions for both age groups included providers 
counseling parents on the HPV vaccine and seeking more information on the HPV 
vaccine, as hypothesized (Table 10).  
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Table 10 
Most Commonly Reported HPV Vaccination Activities for Girls 9-12 and 13-17 
 (N = 227) 
 
 Category on Variable % Yes to Activity 
  Age Group                                                                         9-12             13-17 
Counseled parent on HPV vaccine   93.4               94.2 
Sought more information on HPV vaccine   76.4               81.7 
Counseled parent on VFC program   55.2               54.9 
Asked nursed to counsel parent on HPV vaccine   37.7               42.4 
Referred to public health clinician for HPV vaccine   24.5               27.7 











Descriptive statistics confirmed the hypothesis that financial burden and concerns 
about patients’ negative perceptions of the HPV vaccine were the most frequent 
barriers reported by providers (Table 11).  
Table 11 
Most Commonly Reported Barriers for Girls 9-12 and 13-17 (N = 227) 
 
Category on Variable % Yes to Barrier 
Personal (i.e., Provider) Barriers                                                                     9-12     13-17              
Limited knowledge on HPV vaccine   21.5       18.6 
Limited knowledge on state policy initiative   15.8       15.5 
Belief that media is marketing HPV vaccine too much   14.4       13.6 
Concern about Merck’s products or lobbying efforts for Gardasil   14.8       13.2 
Personal discomfort talking with parents about HPV vaccine   10.5         6.4 
Professional Barriers 
Concerns about financial burden of HPV vaccine on patients and self   43.3       44.1 
Concerns about  patients’ negative perceptions about HPV vaccine   35.2       32.3 
Concerns about safety of HPV vaccine   23.3       21.4 
Concerns about state HPV policy initiative or lack of initiative   21.0       20.5 
Concerns about effectiveness of HPV vaccine   21.4       18.2 
Concerns about vaccine reducing future pap screenings     9.0       10.9 
Concerns HPV vaccine is outside the providers’ scope of practice     2.4         2.3 
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The hypothesis regarding the most frequent supports reported by health 
providers’ was partially confirmed, with personal belief in the positive impact of the 
HPV vaccine found to be the most commonly reported support and adherence to 
professional recommendations as the third most frequently reported support for both 
age groups (Table 12). However, contrary to the prediction that the state policy 
initiative would be one of the most frequently reported supports, it was sixth on the 
list. Instead, personal comfort talking with parents about the HPV vaccine, positive 
exposure from the media on the vaccine, and extra information provided by employer 
came ahead of state policy initiative.  
Table 12 
Most Commonly Reported Supports for Girls 9-12 and 13-17 (N = 227) 
 
 
Category on Variable % Yes to Support 
Personal (i.e., Provider) Supports                                                                  9-12           13-17 
Belief that vaccine will have positive impact on young women’s lives   84.3             85.2 
Comfortable talking with parents about the sexual nature of the 
vaccine 
  69.0             72.2 
Positive exposure from media on HPV vaccine   64.8             63.7 
Positive experience with HPV vaccine (e.g., daughter vaccinated)   36.7             38.6 
Professional Supports 
Adherence to Advisory Committee on Immunization Practices (ACIP) 
recommendations 
  66.7             66.5 
Extra information provided by employer on the vaccine   61.0             61.0 
State policy initiative aimed at promoting vaccine   45.7             47.0 
Ability to provide vaccine free/reduced fee to non-Medicaid patients     41.4             42.7 
Internal or external forum with other clinicians to discuss the vaccine   38.1             38.5 
Presentation by social worker or medical professional on talking with 
parents 
  15.7             17.9 
Presentation by  social worker or medical professional on financial 
options for vaccine 
  12.9             13.8 
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For the two open ended questions that asked about the most important barriers 
and supports to HPV vaccination, Atlas software was used to qualitatively code the 
responses and then determine those barriers and supports most frequently reported. It 
should be noted that the results may not be representative of the sample, given that 
less than half of the respondents answered these open-ended questions. The 
hypothesis that the financial burden would be the most important barrier was not 
supported, as patients’ (i.e., parents and youth) negative perceptions of the vaccine 



































Type of Barrier Frequency 
Patient Negative Perceptions of HPV Vaccine 89 
      Parent Discomfort with Sexual Nature of Vaccine 
         “Parents refusing vaccine: ‘They don’t need it this early’,   
        ‘They would never get HPV’ 
         “Parental concerns that when their daughter gets the vaccine it is a license to have sex” 
         “Social stigma associated with sexually transmitted diseases” 
         “Parents don't want their kids to have a shot that protects them against STD’s.” 
         “Parents often uncomfortable and wish to delay” 
Financial Burden of HPV Vaccine 62 
       Cost for Patient and Provider 
          “Cost to the patient if not covered by Medicaid, especially  
            those who are undocumented immigrants” 
          “Reimbursement from insurance companies/parents can’t pay” 
          “No coverage for vaccine in LA by Medicaid” 
           “Cost—we order vaccine when requested by parent—do not keep on hand”  
           “Poor reimbursement to private practice by Medicaid” 
           “Cost—New Mexico Medicaid slow to cover the cost of HPV vaccine” 
Safety of HPV Vaccine 24 
         Safety Concerns of Parents and Providers 
            “Newness of vaccine, and perceived ‘uncertainty’ of safety (not efficacy) of vaccine” 
            “Parents perception that the patient should wait and see if this  
             vaccine is going to have long term consequences negatively” 
Effectiveness of HPV Vaccine 20 
        Effectiveness Concerns of Parents and Providers 
             “Length of time of coverage” 
             “Long term studies for proof of effectiveness” 
             “When/if a booster is necessary” 
             “Concerns about effectiveness of vaccine after patient has  
               two or more partners or abnormal pap” 
Similarly, the hypothesis that the state policy initiative would be reported as 
the most influential support was not supported. Rather, the personal belief in the 
positive impact of the HPV vaccine on young women’s lives was reported to be the 
most important support in HPV vaccination (Table 14). Despite the small number of 
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respondents to these open-ended questions, the results are in line with the overall 
findings about most commonly reported barriers and supports.  
Table 14 
Most Influential Supports to Aiding Vaccination of Girls 9-17, with Exemplary 
Quotes 
 
Type of Support Frequency 
Personal Belief of Positive Impact of HPV Vaccine 45 
      Provider’s personal beliefs on benefit of HPV vaccine 
        “Personal belief saving lives with vaccine” 
        “Personal belief that vaccination is the right thing to do” 
        “Impressed with it as first vaccine to make significant impact on  
         female health” 
         “Personal belief it will reduce ‘bad paps’ and eliminate cervical 
          cancer in young women” 
        “I am a huge advocate due to the cost of gyn visits I see each  
         year due to HPV” 
Being Able to Provide HPV Vaccine Free or Discounted 25 
       Using public and private monies for covering vaccine costs 
         “Financial assistance availability” 
         “Free vaccine from VFC” 
         “Sliding scale fee to those without insurance coverage to cover cost” 
         “Wide insurance coverage of the vaccine”  
         “Free vaccine from state” 
         “Universal purchase state—thus no cost” 
Recommendations from Professional Associations 22 
         Providers following professional recommendations 
           “ACIP and AAP recommendations” 
           “Recommendations from ACOG [American College of Obstetricians and     
Gynecologists]” 
Support Services from Merck 21 
        Providers receiving support from Merck 
           “Representatives from Merck have visited numerous times to talk  
            about the HPV vaccine” 
           “Merck rep education materials, professional and patient-oriented” 
           “Merck staff support with packets in English and Spanish” 
           “Merck reps put us in contact with MD’s who can answer questions” 




Research Question E: 
The final research question sought to identify the best predictors of 
vaccination rates for each age group and whether there were any significant 
interaction effects between the predictor variables. The four predictor variables 
included the type of provider, the type of state policy initiative, the overall barriers 
score, and the overall supports score. Type of provider was changed into dummy 
variables as it was a nominal variable. The interactions included in the analyses were 
between 1) type of provider and type of state policy, 2) type of provider and overall 
barriers scores, 3) type of provider and overall supports scores, 4) type of state policy 
and overall barriers scores, and 5) type of state policy and overall supports scores. 
There were two sets of interaction variables, one for each age group. There were nine 
steps or models in each of the regression analyses, with the Enter method used for 
both analyses. The Enter method places each predictor variable one at a time into the 
model without considering whether it significantly contributes to the model (Mertler 
& Vannatta, 2005). The criterion variables were the vaccination rates for each age 
group.  
As mentioned earlier, the distributions of data on the overall barriers scores 
and overall supports scores variables were not skewed. On the type of provider 
variable, as mentioned earlier, there was an overrepresentation of nurse practitioners 
and an under-representation of physician assistants in the sample, according to their 
proportional representation in the sampling frame. Additionally, within each state 
there was a great deal of variance in the vaccination percents by type of health 
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provider for each age group (see Table 15). Family physicians, gynecologists, and 
pediatricians tended to report higher vaccination percentages than nursing 
practitioners and physician assistants. Louisiana was the only state that did not have 
any responses by one type of health provider (i.e., Physician Assistants).  
Table 15 




Variable NC LA NM TX Overall Mean 
Vaccination by 
Provider Type 
     
Girls 9-12      
Gynecologist 46.0 (45.20*) 32.8 (39.20) 25.0 (50.00) 15.0 (23.81) 29.7 
Pediatrician 27.1 (26.65) 48.8 (39.96) 19.6 (21.85) 31.4 (29.50) 31.7 
Family Physician 34.7 (31.42) 30.2 (30.56) 35.3 (29.85) 30.8 (32.25) 32.8 
Nurse Practitioner 29.4 (33.95) 30.9 (31.39) 24.6 (31.56) 21.8 (21.60) 26.7 
Physician 
Assistant 
25.3 (20.19) ----** 19.5 (17.65) 15.0 (15.41) 19.9 
Overall Mean  32.7 35.5 25.6 24.7  
Girls 13-17      
Gynecologist 73.0 (21.37) 32.8 (21.69) 40.0 ( 45.46) 43.8 (47.85) 47.4 
Pediatrician 61.2 (35.19) 63.4 (36.97) 43.9 (32.83) 38.1 (24.51) 51.7 
Family Physician 58.1 (29.12) 34.6 (27.42) 46.3 (26.42 ) 41.9 (35.62) 45.2 
Nurse Practitioner 52.8 (38.98) 40.0 (34.09) 40.5 (32.22) 28.7(25.95) 40.5 
Physician 
Assistant 
33.8 (27.99) ----** 36.0 (29.02) 29.0 (20.13) 32.9 
Overall Mean  55.8 45.0 39.6 36.6  
**No responses from Physician Assistants in Louisiana  
 
In order to determine whether a multiple regression analysis was appropriate, 
Spearman correlation tests were conducted on the four predictor variables, one test 
 102
for each age group, and from those tests multicollinearity was not found to be a 
problem. Further, tolerance statistics confirmed this after running the multiple 
regression analyses.  
The first multiple regression analysis examined the influence of the predictor 
variables on vaccination rates of girls aged 9-12. The only predictor variable that 
made a statistically significant contribution to the model was the overall barriers 
scores for girls 9-12. The coefficient statistics on this variable are presented in Table 
16. Notably, there was a negative relationship between overall barriers scores with 
vaccination rates of girls 9-12. This suggests that when controlling for the other 
predictor variables, fewer barriers are predictive of higher vaccination rates.  
Table 16 
Coefficients for Final Model 
Predictor Variable B β t p R2 Adj. R2 
Overall summed 
score of barriers 
girls 9-12 
-3.795 -.277 -3.756 .000 11.4 8.4 
The second multiple regression analysis examined the influence of the 
predictor variables on vaccination rates of girls aged 13-17. Two predictor variables 
made a statistically significant contribution to the model. In this model, 9.2% (R2) of 
the variance was explained in the dependent variable (Adjusted R2 = 6.3%). The first 
was the overall barriers scores for girls aged 13-17 and the second predictor was type 
of provider. The coefficient statistics on this variable are presented in Table 17. 
Again, there was a negative relationship between overall barriers scores with 
vaccination rates of girls 13-17. This further confirmed that when controlling for the 
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other predictor variables, fewer barriers are predictive of higher vaccination rates. For 
the second predictor variable, being a pediatrician was predictive of increased 
vaccination rates.  
Table 17 
Coefficients for Final Model 
 
Predictor Variable B β t p 
Overall summed score of 
barriers girls 13-17 -4.070 -.266 -3.803 .000 
Type of Provider--




The importance of these findings is that there is combined evidence pointing 
to the importance of reducing a variety of barriers to HPV vaccination.  
When a bivariate correlation matrix was produced with the four predictor 
variables and the dependent variables, there was a significant negative relationship 
found between overall barriers with vaccination of girls ages 9-12 and 13-17. This is 
important to consider, particularly for the older age group, in that controlling for the 









Chapter 6: Implications and Conclusions 
This specific study makes a significant contribution to the literature, as it is 
the first to combine a sample of differing health provider positions to determine what 
percent of their female patients they had vaccinated against HPV. Additionally, this is 
one of the first studies to look at the implications of public policy on HPV 
vaccination as well as current perceived barriers, supports, and actions of health 
providers, as opposed to perceptions based on a hypothetical scenario.   
Consistency with the Literature on HPV Vaccination Intentions 
Results from this study indicate that vaccination rates for girls 9-12 and 13-17 
did vary from one another significantly, with the older group having higher 
vaccination rates in New Mexico, North Carolina, and Texas. This was to be 
expected, given that the literature on intentions to vaccinate against HPV clearly 
favors older female adolescents as compared with pre-adolescent girls (refer back to 
Chapter 3 for Review on Literature). Comments made in the open-ended questions 
reflect some degree of discomfort from both providers and in particular, parents, with 
vaccinating pre-teen girls against HPV.  
Additionally, the second most frequently reported barrier by providers was the 
negative perceptions of the HPV vaccine by their patients and, most often, the parents 
of patients. Consequently, it is not surprising that a frequently mentioned support for 
vaccination by providers was being comfortable talking with parents about the sexual 
nature of the HPV vaccine. Given that the CDC has specifically recommended 
targeting pre-adolescent girls ages 11-12, this dissonance will need to be addressed to 
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increase the comfort level of both stakeholders. Social workers employed in health 
care settings have a unique opportunity to present ways for providers to talk with 
parents about the HPV vaccine and how to address parents’ concerns about the sexual 
implications of the vaccine. Additionally, social workers can collaborate with health 
providers by promoting accurate information about HPV when working with parents 
and discuss any concerns about talking with their pre-adolescents about the vaccine.  
Consistency with the Theory of Planned Behavior Constructs 
While some providers have reservations that may inhibit vaccination, findings 
show that providers who vaccinate at a higher percent in one age group tend to 
vaccinate the other age group at a higher rate as well. The Theory of Planned 
Behavior would suggest that these providers may have personal beliefs that are 
positive toward vaccination, either towards vaccination in general or specifically for 
HPV because of the positive impact it can have on reducing cervical cancer; this was 
confirmed in the findings, in which participants reported the most common support 
for vaccination is the positive personal belief that vaccination would have a positive 
impact on young women’s lives.  
The Theory of Planned Behavior would also suggest that providers may tend 
to vaccinate at higher rates when they internalize the subjective norms of their peers 
and profession (i.e., other providers and the CDC or AAP) as highly influential. 
Again, this study reveals that normative beliefs were important, as adhering to 
professional recommendations was the third most commonly reported support.  
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The last construct in the Theory of Planned Behavior suggests that providers’ 
vaccination rates would be directly related to their sense of self-efficacy. The survey 
questions aimed at understanding the self-efficacy of providers were those that 
focused on the availability of both internal and external resources to discuss and offer 
the vaccine to patients (e.g., information provided within employment site about the 
vaccine; personal comfort level talking with parents about the vaccine). This latter 
statement is also supported by the findings, in which an increased barrier scores were 
predictive of reduced vaccination by providers serving girls aged 9-12 and 13-17 
when controlling for type of state policy initiative, type of provider, and number of 
supports received. Further, the second most commonly reported support was the 
personal comfort level of talking with parents about the vaccine. This finding is 
suggestive of higher perceived behavioral control, in terms of the self-efficacy of 
counseling parents. Given that higher levels of comfort talking with parents was 
associated with personal beliefs that the vaccine has a positive impact for both age 
groups, it would follow that these two aspects are important factors that influence 
vaccination behaviors.  
 In addition, this study suggests that providers’ serving a higher proportion of 
patients using private insurance as well as public insurance or monies to pay for the 
HPV vaccine is predictive of higher vaccination for girls 13-17. This may be 
attributed to the perceived behavioral control aspect of the Theory of Planned 
Behavior, in that providers may be more willing to offer the vaccine to youth if they 
perceive patients’ families as being able to use private insurance to cover at least part 
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of the cost. Providers’ perceived behavioral control may diminish when financial 
barriers are presented, which appears to be quite often, given that financial burden 
was reported as the second most commonly reported barrier to vaccination for both 
age groups. Consequently, perceived behavioral control aspect will be enhanced when 
providers working with families who do not have the resources to pay for the vaccine 
are eligible for the VFC program. It may be that providers vaccinate those both 
privately and publicly insured, however, there may be families, such as working-class 
families, who do not qualify for VFC and/or who are underinsured.  
Interestingly, in New Mexico, the only state examined with a mandate for 
health insurance coverage for girls 9-14, and the state whose majority of providers 
reported their patients using public funds for HPV vaccination (the highest among all 
four states), there were still lower vaccination rates for both age groups than either 
North Carolina or Louisiana. This raises the question as to why the initiative is not 
being utilized, perhaps as a result of lack of education to providers and patients about 
the state policy initiative. Further, New Mexico is one of the states that have a 
universal coverage policy for required vaccines, which means that all required 
vaccines are provided free of charge to any children 18 years and younger, regardless 
of insurance status (Gudeman, 2007). Since the HPV vaccine is not required, it is not 
included in this universal coverage policy. If it did include this vaccine, it would be 
expected that the percent of patients using public funding for obtaining the vaccine 
would be much higher.  
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North Carolina is also a universal immunization state (Gudeman, 2007). 
However, since the HPV vaccine is not currently required by the CDC but rather is 
recommended, only those youth who qualify for the VFC program are able to access 
the HPV vaccine free of charge. If the CDC adds the HPV vaccine to the required 
immunizations list, then it is likely that the vaccination rates will increase in this state 
once the financial burden is eliminated.  
Additionally, there may be reduced perceived behavioral control when 
providers perceive the vaccine as a financial risk or liability for the clinic they work 
for or themselves when they are self-employed. While a majority (63%) reported 
spending $10,000 or less on the HPV vaccine, the remaining third have spent 
exceedingly more to purchase and store the vaccine. In addition, 58% reported 
requesting an increased vaccine supply, and almost 30% reported keeping their HPV 
vaccine supply low to protect against financial loss.  
The Role of State Policy 
The effort to understand the role of state policy on vaccination behaviors of 
providers is preliminary given the lack of current research. When state policy was 
considered in this study, the difference in vaccination rates was significant only for 
providers vaccinating 13-17 year-old girls.  
Attention to state policy by social workers and public health workers may be 
important, however, there is not a definitive answer as to the role of state policy on 
provider vaccination. This is highlighted in the results of the study, in that providers 
in Louisiana, which has no state policy initiative, reported higher vaccination 
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percentages than either New Mexico or Texas. Louisiana could have higher reported 
vaccination rates over New Mexico and Texas for three reasons. First, it could be that 
it is too early to see the impact of state policy initiatives aimed at promoting the 
vaccine in these two states. Implementation of state level policy is a slow process that 
can take can months to years to be fully integrated across the entire state. Second, it 
could be that the policies aimed at promoting vaccination in New Mexico and Texas 
are not having the intended effect. Providers in New Mexico reported the lowest 
percentage of patients using private insurance to pay for the vaccine. This is 
counterintuitive, given that the state policy initiative is intended to encourage 
vaccination by mandating private health insurance coverage for the vaccine. It could 
be that there has been limited dissemination by policy makers, health insurance 
companies, and Merck to providers and patients that this coverage is available. It may 
also be that despite the coverage offered, the remaining financial burden is still too 
heavy for consumers to pay, given that the state policy does not require complete 
financial coverage of the vaccine (deductibles and co-insurance payments apply). In 
Texas, it could be that because there was not an appropriation of funds assigned to the 
passed legislation mandating education of the public, the policy it is not having the 
desired impact. With no additional resources offered to the Texas Health Department 
to disseminate the educational materials, it may be that it has had a limited effect thus 
far.  
Third, it could be that Louisiana, with no policy initiative, was actually a 
better environment for vaccination than having a state that had taken legislative or 
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executive action against the vaccination mandate for school enrollment. Given that 
New Mexico and Texas had the lowest vaccination rates and both shared the veto 
against the vaccination mandate for school enrollment, it may be that that form of 
social policy did play a negative role in vaccination, thus leading Louisiana to come 
out ahead of both of these states. Considerations regarding the role of social policy 
should include the extremely dynamic nature of publicizing and implementing state 
policy on the HPV vaccine; across the country, there has been incredible movement 
within and between states in terms of the modification, addition, and deletion of 
initiatives. Both Texas and New Mexico have the historical context of being the first 
two states in which the mandate of the vaccine for school enrollment failed with 
enormous public attention. In connection, controversy around Merck’s role in the 
pressure to implement a vaccine mandate as well as the morality politics of a vaccine 
to prevent an STD may be influential. Both states effectively made a mandate in the 
near future improbable, perhaps unwittingly negating the influence of less 
controversial policy initiatives that were later implemented (i.e., health insurance 
coverage and an educational materials on the Internet and to school nurses).  
Alternatively, it is possible that state policy does have an impact, but that this 
study was unable to detect the effect it had on vaccination rates. One reason for this 
could be that the survey did not ask enough specific questions about each state’s 
policy initiative(s) to be able to clearly separate out the effect of it on vaccination 
rates. It could also be that since fewer barriers were predictive of higher vaccination, 
that a reduced overall barriers score was actually a proxy for the positive effect of 
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state policy, particularly as questions about barriers asked about the financial burden 
of the vaccine, the negative perception of the vaccine by patients (which can be 
reduced through education), and limited knowledge of the provider (which may be 
reduced through dissemination of education as well). Another reason may be that the 
sample was not large enough to reflect the impact of a state-wide policy initiative, 
and that with a larger, more state-wide representative sample, the effect of policy 
could more effectively captured.  
Application to Social Work 
Social workers are often on the front lines of health care service provision, 
whether it be in a hospital setting, free healthcare clinic, or public health department. 
Social workers who are employed in schools, mental health centers, residential or 
group homes, or in child welfare frequently interact and collaborate with health 
providers who are providing health care services to their clients. Further, social 
workers are often in management or administration positions within these types of 
settings and may even supervise health providers. For these reasons, along with social 
work’s interest in disease prevention, as evidenced by the discussion of increasing 
numbers of joint public health and social work graduate degree programs (Bracht, 
2000), it is important to consider the role social workers can play in supporting those 
interested in HPV vaccination, such as consumers and health providers. To assist with 
the development of primary prevention activities, education and social change within 
the community, collaboration and consultation between those in social work, the 
public health arena, and primary care providers will be critical.  
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One area that social work can offer assistance is education and dissemination 
of information to consumers, health providers, and to health service oriented 
agencies. Providers frequently reported counseling parents on the HPV vaccine, 
which is not surprising given the high percentages of parents and young women who 
report limited knowledge about the causes and consequences of HPV (see Chapter 3 
for Literature Review). Social workers can help to triangulate that information by 
educating themselves about HPV and the vaccine and offering education to their 
clients, particularly to parents and to young women. Some parents or community 
groups may see this as promoting the vaccine, which is controversial given that this 
issue manifests itself in the context of sexual behavior of young people, an area that is 
often taboo and unacknowledged. It is important to validate clients’ realities that this 
is an uncomfortable topic, but that having accurate information is necessary to 
making an informed decision. This may be useful particularly for those patients who 
may encounter a health provider who also has limited information about HPV and the 
vaccine. In this sample, approximately 20% of the providers reported the barrier of 
having limited knowledge of the HPV vaccine and even more reported seeking 
additional information about the HPV vaccine as an action. It is likely that if a 
provider is not educated about HPV and/or the vaccine, the provider may not initiate 
a conversation about it to patients.  
In connection with counseling parents, more than half of providers reported 
counseling parents on the VFC program. Since patients may be unaware that they are 
eligible to qualify for this program, social workers who are employed in health care 
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settings or in schools may educate consumers about the eligibility requirements and 
refer clients to VFC registered clinics.  
Additionally, for those social workers who are working in medical settings or 
who are administrators in such settings where vaccination is occurring, it may be 
useful to provide specific supports for providers in that clinic or to educate local 
clinics about the benefits of such supports. Specifically, receiving extra information 
about HPV and the vaccine was reported as the second most common support. 
Offering this type of support may lead to an increased sense of self-efficacy by 
providers and thus lead to increased service utilization by patients. When extra 
information is provided in such contexts, addressing safety concerns about the HPV 
vaccine will be important, given that such concerns were reported as the third most 
common barrier to vaccination. Given the newness of the vaccine, part of that 
concern appears to stem from the absence of longitudinal data on possible future side 
effects of the vaccine. Bringing in medical professionals who worked with the clinical 
trials of Gardasil™ or representatives from Merck may reduce such concerns. 
Recommending that extra information be provided at conferences held by 
professional associations, such as the American Academy of Nurse Practitioners 
(AANP) or the American Association of Family Physicians (AAFP), may also be part 
of this process. Particularly as nurse practitioners and physician assistants tended to 
vaccinate at lower rates than pediatricians, family physicians, or gynecologists, it may 
be that these two groups may need additional support. Given that being a pediatrician 
was predictive of higher vaccination rates in this study, it would be worthwhile to 
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investigate further the differences in attitudes and behaviors by type of health 
provider.  
The Theory of Planned Behavior would suggest that in order to increase 
vaccination rates, the personal beliefs and subjective norms will need to be positively 
oriented toward vaccination and that both providers and parents would need to have 
perceived behavioral control (i.e., feel self-efficacious)  to utilize the vaccine. This 
may be complicated, particularly in vaccinating pre-adolescent girls, by the taboo 
nature of the HPV vaccine. Providers and patients’ personal beliefs may be 
influenced by their religious or moral ideologies that lead them to resist the HPV 
vaccine because HPV is sexually transmitted. Giving the vaccine acknowledges the 
inherent sexual self of the recipient of the vaccine. This can be an uncomfortable 
acknowledgement for parents and providers. Similarly, the social norms supported by 
religious groups may again not support the vaccine because of its connection to 
sexuality. These beliefs may certainly influence the level of perceived behavioral 
control by parents and providers, as they may not have accurate information or they 
may have conflicting information presented.  
Social work is about breaking down communication barriers and talking about 
topics that are taboo. The importance of actively listening and effectively 
communicating with providers and parents about this issue should not be 
underestimated. It may be that the decision to get a pre-teen vaccinated is a source of 
great stress between couples or between a teenager and her parent. The tension of this 
vaccine in terms of the cultural norms and the symbolic meaning behind vaccination 
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is palpable. This is evident in the literature, but also in the conversations this 
researcher has had with friends, family members, and colleagues about this study, in 
which many questions and discussions have arisen about whether vaccinating is the 
“right thing” or what age is the “right age” and whether the vaccine will pose safety 
concerns in the future. Stepping away from the morality debate, the reality of the 
situation is that providers and consumers will be asked to adapt to this new 
technology as it becomes fully integrated into the immunization schedule for pre-
adolescent and adolescent girls. Further, it is likely that in the near future, the vaccine 
will become available for males in the U.S., as the vaccine has already been approved 
in Australia for males 9-15 (Australian Department of Health and Ageing, 2006). As 
with any new technology that has come to fruition, such as the Hepatitis B vaccine, or 
that will be developed in the coming years, such as an HIV vaccine, there will be 
need to be a clear assessment of what factors promote successful adaptation and how 
to create an infrastructure for these factors to be highly integrated into the health care 
system.  
Limitations of Study 
The implications of this study need to be considered within the constraints of 
the limitations.  
Sampling Bias 
Given that there were not lists available of healthcare providers working with 
girls in the two age groups of interest, the lists obtained from each state’s medical and 
nursing boards included additional healthcare providers who were not part of the 
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target population. While these lists were comprehensive, they did include only those 
who providers who allowed their information to be released. Further, the lists were 
purchased in January 2007, and each list was updated by the boards in 2007 either 
annually, bi-annually, or quarterly. Thus, given that there were many “return to 
sender” responses, it is likely that some healthcare providers did not contact the state 
boards to update their information, such as if they relocated out of state or 
discontinued practicing. While a random sample was selected from these lists, it is 
apparent that the final sample was not entirely random. This limits the ability to 
generalize to all healthcare providers who work with girls in these two age groups.  
Response Rate 
While the response rate of 15 percent did fall within the range seen in the 
literature for this population, it leads to questions about whether the results are 
generalizable to the entire sample and beyond that to providers not surveyed in the 
four states. Two factors may have contributed to the low response rate. First, the lists 
obtained from each of the state’s nursing and medical boards had limited information 
about each provider, particularly about their specialty. Thus, it was not surprising that 
returned surveys included a range of individuals either no longer employed or who 
were not working with the target population. New Mexico had the highest percents of 
returned surveys that were non-target population providers---as high as 44% for 
Physician’s Assistants, which can be attributed to the minimal information provided 
by the boards in this state; only the names and addresses were provided for 
physicians, physician assistants, and nurse practitioners. Thus, it is likely that had the 
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sample been recruited through other additional means, such as going through each of 
the lists and determining which fit the target population through brief phone calls to 
each provider, there may have been a higher response rate. It is likely that many of 
those who were non-respondents fell into this category of not working with girls in 
the target age groups.  
The technical difficulties that prevented the successful utilization of the online 
survey were unexpected and certainly limited some respondents from participating in 
the process. It is likely that some participants may have gotten frustrated with the 
online process, perhaps resulting in a lack of participation in the follow-up mailing. In 
connection with this, the response rate most likely would have been higher had there 
been additional follow-ups. One follow-up mailing was sent to each of the 
respondents. Additional follow-up mailings were not sent due to budgetary 
constraints. Since the online survey process did not continue, additional unexpected 
costs were associated with the follow-ups, as a stamped return envelope had to be 
provided along with the actual mail survey, which would not have been needed had 
the online survey worked. Had the online survey been successful, it may have 
increased the initial response rate as well, thus decreasing the need to expend further 
resources on follow-ups.  
Missing Data and Distribution of Data 
Aside from the response rate, there was missing data in the variables that were 
used for the analyses, though for most variables it was minimal. The three variables 
with the most missing data were 1) the percent of vaccinated female patients using 
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public funding to pay for the vaccine (missing 33 cases, 14.5% of sample), 2) percent 
of vaccinated female patients using private insurance to pay for the vaccine (missing 
32 cases, 14.1% of sample) and 3) percent of patients aged 9-12 vaccinated (missing 
23 cases, 10.1% of sample). When the missing data for these three variables were 
replaced with the means of these variables for each state, and the analyses that 
included these variables were re-run, the results did not differ greatly and no 
additional significant differences were found.  
In terms of assuming normality, some of the primary variables used for 
analysis did not reflect a normal distribution, as demonstrated with histograms. Two 
variables had high numbers of cases on either end of the distribution, including 
percent of patients who used private insurance to pay for the HPV vaccine and 
percent of patients who used public monies to pay for the vaccine. This demonstrates 
that patients typically rely on either private or public insurance for health services. 
Additionally, the variable asking percent vaccinated for girls 9-12 was positively 
skewed, with a majority of providers reporting that they had not vaccinated any girls 
in this age group. This was in contrast to the variable that asked percent vaccinated 
for girls 13-17, with a majority of providers reporting percentages of vaccinating 50% 
and 100% of their patients in this age group. This highlights the need for further study 
with the same population to determine whether the data collected on these variables 
represented typical responses by providers or if it was unique to this sample. Still, as 
indicated earlier, the multivariate statistics used in this study are robust against non-
normal data, thus limiting the likelihood that it affected the results.  
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Measurement Limitations 
Recognizing the limitations of the actual survey instrument is also important. 
Given that this was the first survey to ask these specific questions, there was limited 
information about potential weaknesses in the survey questions and structure apriori. 
After getting the data, it was clear that certain questions on the survey were worded in 
such a way that did not lend itself to getting the most accurate information or that 
provided enough information for specific analyses at the state level. For example, if 
there had been a question that inquired how many female patients providers had in 
their practice, it would have allowed for a further calculation of an actual HPV 
vaccination rate for each provider, which could have been used in a calculation of a 
state HPV vaccination rate. Additionally, in an attempt to keep the survey short, 
questions about the two age groups were in adjoining columns (see Appendix G), thus 
leading to very similar answers for both age groups on activities, barriers, and 
supports. A possible reason for this was perhaps acquiescence bias, rather than an 
accurate reflection of the variance in behaviors and attitudes.  
Further, while the state was used as an independent variable synonymous with 
the state policy initiative, it is quite possible that other aspects of the state could be 
causing a spurious relationship between differences in providers’ reported vaccination 
percents. Other local factors could play a role, such as whether providers worked in a 
county or region that has a high concentration of medical shortage areas or higher 
percent of individuals in poverty. Also, since there was more than one state policy 
initiative in both New Mexico and Texas (the action against the school mandate along 
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with the current policy initiative), it is difficult to assess which had more influence, 
since it was not asked on the survey. It would have been useful to include a brief 
statement about each state’s past and current policy initiatives and then ask a specific 
question about the positive and negative influence of each on provider’s vaccination 
behaviors.  
Accuracy of Data 
Another consideration is that the data from providers may not have been 
completely accurate. While the small pilot test did show that a majority of providers 
believed that would be able to accurately report vaccination rates and use of private or 
public insurance to pay for the vaccine without consulting their medical records (see 
Appendix C), it may not have been reflective of the entire sample. Without verifying 
the medical records of each provider, there is no way to know for sure whether the 
providers may have over-estimated their vaccination rates. Additionally, they may 
have over-estimated for the questions asking the percent of their patients aged 9-17 
who were minority patients and percent who were private insurance patients. 
Utilizing case records for future studies would vastly improve the confidence in the 
responses provided to these questions. Also, having a large portion of the survey use 
questions that were answered “yes” or “no” limits the accuracy of the data in that if a 
provider reports “yes” they have counseled a parent on the VFC program, it does not 
provide further information as to whether the provider engaged in this activity more 
than once or how often. Similarly, in asking “yes” or “no” responses for the questions 
related to personal and professional barriers and supports, respondents were not given 
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the opportunity to rank the barriers or supports or to indicate to what frequency or 
degree it occurred. While the most influential barrier and support was asked, more 
than half of respondents did not respond to this question.  
Future Directions 
This study provides an important starting point for future research that will 
examine the various factors associated with HPV vaccination of females 18 years and 
under. Future researchers can take from this study the known barriers and supports 
that have been identified as most influential in HPV vaccination and begin to 
determine whether that is generalizable outside of these four states. If so, the Theory 
of Planned Behavior can continue to serve as a foundation in which personal and 
professional barriers and supports can be examined in terms of their causal 
relationship to HPV vaccination. Still, other state policies that have been 
implemented elsewhere in the U.S. should be examined, such as in New Hampshire 
and Washington, where state legislatures appropriated funding to give the vaccine to 
a certain population of females. Additionally, states across the country are continuing 
to propose new legislation, such as mandated health coverage and thus studies can 
continue to research the impact of state policy on vaccination rates. In particular, 
studies should focus on what initiatives and interventions reduce the financial burden 
of the vaccine, particularly as it may be several years before a generic vaccine is 
available. It does appear evident that both providers and patients are impacted deeply 
by the cost of the vaccine.  
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Given the limited resources in state health departments, it is important for 
scholars to advise state policy makers as to whether there should be significant 
financial resources appropriated for state policy initiatives. In addition, since the 
proposed vaccination mandate for school enrollment has not yet been dismissed and 
may actually be implemented in the near future, it will be important to longitudinally 
evaluate the impact of that mandate, both on the perceptions of stakeholders and on 
vaccination rates.  
Longitudinal studies on girls in both age groups will need to be conducted to 
determine whether the fears of parents that the HPV vaccine will lead to increased 
sexual activity is accurate. Similar to the comprehensive sexual education debate, 
even though longitudinal studies have demonstrated this form of education to be 
associated with reduced unintended pregnancies and sexually transmitted diseases, 
parents still believe it leads to sexual promiscuity (McCave, 2007b). In considering 
resistance to the HPV vaccine, particularly for parents of pre-adolescents, the 
importance of parents’ beliefs will be critical. Understanding parents’ personal beliefs 
as well as the influence of subjective norms (resistance to the vaccine by parents’ 
peers, family members, clergy, etc.) may well play a vital role in whether parents 
vaccinate their daughters. 
In addition, educating providers about specific state policy initiatives will be 
important, particularly as there may be an increase in research to determine the 
impact of state policy and what leads to the successful implementation of social 
policies. Some providers in Louisiana indicated that the state policy was in fact a 
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support; however, there is no state policy initiative in this state. Providers may not 
have the most recent information about the policy in their states. This is to be 
expected given the extremely volatile nature of the public policy realm that is difficult 
to follow without continual checking of key online sources that tracks the HPV policy 
initiatives. Future studies could determine the knowledge levels of providers 
regarding state policy initiatives and specific attitudes about potential policy 
initiatives.  
Further, given that the HPV vaccine will most likely be made available for 
males in the next several years, it will be necessary to determine the impact of this 
new advance in technology, particularly as it will take the burden off of women only 
and perhaps draw attention to the universal risks for both females and males. Once 
the vaccine is available for males, further research into the intentions and behaviors of 
heterosexual and gay men will be important, as they are at risk for penile and anal 
cancer from HPV (Dunne, Nielson, Stone, Markowitz, & Giuliano, 2006). 
While Physician Assistants were included for the first time in this study, 
additional health care providers may be considered in future research studies. 
According to McIntosh, Sturpe, and Khanna (2008), pharmacists should be 
considered as another type of provider who could act as a gatekeeper for the vaccine, 
as pharmacists are licensed in 46 states to administer vaccines. Since the vaccine is a 
three dose series, it can place added burden on both the physician and patient to make 
those visits; it may seem more reasonable to go to the local pharmacist instead. It 
could also potentially reach more vulnerable patients who have less access to care. It 
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has been recommended that physicians vaccinate their patients with the first two 
doses as well as provide the medical counseling on the vaccine and then have a 
pharmacist give the remaining dose in the community. Future research could examine 
that attitudes and vaccination rates of pharmacists if this becomes a common practice. 
It may be some time before this occurs however, as often pharmacists are often only 
allowed to vaccinate those who are 18 years of age or older, which brings up legal 
issues of consent for vaccination. Further, the influence of morality politics would 
certainly come into play, as was seen when RU486 became available in pharmacies. 
Physicians may also be concerned that patients may miss their check ups or well-
child visits or that specific medical opportunities for discussing STDs and sex would 
be missed if patients received the vaccine in the pharmacy setting (McIntosh, Sturpe, 
& Khanna, 2008). 
Lastly, future research may focus on the unique impact of the various public 
resources that can be utilized to support vaccination, such as the VFC program and 
the money appropriated for states and local jurisdictions through Section 317 of the 
Vaccination Assistance Act (Rein, Honeycutt, Rojas-Smith, & Hersey, 2006).  
Conclusion 
 This study was intended to report the current perceived barriers and supports 
and actual HPV vaccination behaviors of primary care providers serving girls ages 9 
to 12 and 13 to 17 within the context of varying state policy initiatives. A 
proportionate stratified random selection method was utilized to survey pediatricians, 
nurse practitioners, family physicians, gynecologists, and physician assistants in 
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Louisiana, New Mexico, North Carolina, and Texas. While overall response rate (15 
percent) was low, a sizeable number (N = 227) of health providers were surveyed, 
providing important information about which barriers and supports are influential in 
HPV vaccination as well as giving an initial look into vaccination behaviors of 
providers. This study adds to the existing literature that highlights the importance of 
considering barriers and supports, particularly the influence of financial and 
psychological barriers, such as having a comfort level talking with parents about the 
vaccine and its sexual nature. It also points to the significance of personal beliefs, 
specifically having a belief that the HPV vaccine will have a positive impact on 
young women’s lives. Further, the study confirms that adolescents ages 13 to 17 are 
getting vaccinated in higher proportions than their pre-adolescent counterparts. This 
area of research is still in its infancy; much more rigorous research both in the United 
States and abroad needs to be carried out to determine what factors play a significant 
role in increased utilization of the vaccine, particularly for the targeted age group, 11 
to 12 year old girls, as recommended by the CDC. Scholars from public health and 
social psychology will undoubtedly be at the research table. Social work has a unique 
opportunity to join these scholars and be part of the creation of a whole body of 









Health Care Access Indicators Considered in Selecting the Four Study States 
 
Data Compiled from U.S. Census Bureau (2007) and DeNavas-Walt, Proctor, & Lee (2006).  






Louisiana Texas United States 
Ethnic Origins 
(2007 estimates) 
9,061,032 1,969,915 4,293,204 23,904,380 301,621,157
    White 74.00% 84.50% 65.10% 82.6% 80.0%
    Black 21.70% 2.80% 31.90% 12.0% 12.80%
American Indian 
and Alaska Native 
1.20% 9.50% 0.60% 0.7% 1.0% 
 
    Asian 1.90% 1.40% 1.40% 3.4% 4.40% 
 
    Native Hawaiian 
and Pacific 
Islanders 
0.10% 0.10% 0.00% 0.1% 0.20%
Hispanic or     
Latino origin 
    7.0% 44.40% 3.20% 36.0% 15.10%
White persons not 
Hispanic 




$44,772 $41,501 $40,866 $47,563 $50,740
  % Persons below 
Poverty (2007) 
14.30% 17.90% 18.80% 16.3% 13.0%
% W/O Health 
Insurance (2003-
2005 Averages) 




















 New Mexico Stratified Random Sample Selection 
% of Stratification 
 






% of PAs (337/1965) = 17% 17% of 375 = 64 19 83 
% of PEDs (299/1965) = 15% 15% of 375 = 56 17 73 
% of GYNs (176/1965) = 9% 9% of 375 = 34 10 44 
% of FPs (485/1965) = 25% 25% of 375= 94 28 122 
% of NPs (668/1965) = 34% 34% of 375 = 127 38 165 
Total % of Providers = 100% 
Total Stratified 
Sample = 375 
Total Contingency 
Sample = 112   
 
Table 2 
Texas Stratified Random Sample Selection 
 
% of Stratification 






% of PAs (2957/18201) = 16% 16% of 375 = 60 18 78 
% of PEDs (2636/18201) = 15% 15% of 375 = 56 17 73 
% of GYNs (2117/18201) = 12% 12% of 375 = 45 14 59 
% of FPs (5494/18201) = 30% 30% of 375 = 113 34 146 
% of NPs (4997/18201) = 27% 27% of 375 = 101 30 131 
Total % of Providers = 100% 
Total Stratified 
Sample = 375 
Total Contingency 
Sample = 113   
    
 Table 3 
 Louisiana Stratified Random Sample Selection 
 
% of Stratification 






% of PAs (279/3586) = 8% 8% of 375 = 30 9 39 
% of PEDs (734/3586) = 21% 21% of 375 = 79 24 103 
% of GYNs (296/3586) = 8% 8% of 375 = 30 9 39 
% of FPs (938/3586) = 26% 26% of 375 = 98 30 128 
% of NPs (1339/3586) = 37% 37% of 375 = 138 42 180 
Total % of Providers = 100% 
Total Stratified 
Sample = 375 
Total Contingency 




North Carolina Stratified Random Sample Selection 
% of Stratification 








% of PAs (718/5933) = 12% 12% of 375 = 45 14 59 
% of PEDs (1249/5933) = 21% 21% of 375 = 79 24 103 
% of GYNs (1005/5933) = 17% 17% of 375 = 64 19 83 
% of FPs (2328/5933) = 39% 39% of 375 = 146 44 186 
% of NPs (633/5933) = 11% 11% of 375 = 41 13 54 
Total % of Providers = 100% 
Total Stratified 
Sample = 375 
Total Contingency 



































This Study is Approved by the Human Subjects Committee Lawrence Campus, University of Kansas.  
Approval expires 12/4/2008.  
 
           
  January 2008 
 
Hello. You’ve been selected as a valued clinician to offer input on a small but very important 
section of my dissertation survey, of which I will be sending to clinicians like yourself in the 
near future. The survey may even come to you. In order to make sure I get the most accurate 
information from the survey, I am trying to find out how accessible the following questions 
are to someone like yourself.  
 
If you can spare a few minutes, I would greatly appreciate it. All you have to do is think 
about your own practice and try to answer the questions. You don’t even have to put the 
answers down.  Then, just provide your feedback below, place this sheet into the self-
addressed, stamped envelope and you are done!  
 
 
                Please answer the questions below that ask about your HPV vaccination actions. 
 
 
13. Patient Information-- HPV Vaccination Percentage
a What percentage of your female patients aged 9-12 have you vaccinated against HPV? 
 
b What percentage of your female patients aged 13-17 have you vaccinated against HPV? 
 
c Of those female patients you have vaccinated, what percentage have used private insurance to cover part or all of the cost of the HPV vaccine? 
 
d 
Of those female patients you have vaccinated, what percentage have 
received the HPV vaccine for free or at a discount through public 




              1. Would you be able to answer these questions without consulting your patient records?    
Y   or    N 
 
              2. How accurate do you think your answers would be without consulting your patient records? 
    a. Extremely Accurate 
    b. Mostly Accurate 
    c. Somewhat Accurate 
    d. Not Very Accurate 
    e. Unsure 
 
3. If you had to consult your patient records, would that deter you from completing the 
survey?    Y    or   N 
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4. In the space below, please provide any suggestions you have for making these questions 







Thank you for your time! Your input is very important and will contribute to the successful 










































Approved by the Human Subjects Committee Lawrence Campus, University of Kansas.  Approval 
expires one year from 12/4/2007. 
 
                   
 
Hello! I am a doctoral candidate at the University of Kansas, School of Social Welfare. I am 
interested in understanding your perceptions and behaviors with the new HPV vaccine, 
particularly around vaccination of girls between the ages of 9 and 17. You have been selected 
to participate in this study, which involves taking a short survey. The entire process will take 
less than 15 minutes. For every survey completed, $1 will be donated to the American Cancer 
Society, with the potential for $1500 to be donated! In this mailing, you will find a letter of 
support from clinicians like yourself who are familiar with my study.  
 
For your convenience, I have created a secure initial access website with options to 
accommodate your individual preference and that allows for a confidential and anonymous 
process. This site will provide you with the option to continue with the online survey, 
request the survey by fax, E-mail, or postal mail, or to let me know if you do not treat  
pre-adolescent or teen girls. 
 
To complete this process, there are four easy steps: 
 
1. Please type into your internet browser:             http://tinyurl.com/272fnk   
(URL has been changed and shortened for your convenience)  
To protect your confidentiality, you will be asked to enter in the password:     HPV2008    
 
2. Read over the information statement about the study. 
 
3. Enter your unique identifier, which is:  
This number is used only to fill your individual request, as well as for tracking non-
respondents for follow-up mailings. It will not be linked to your answers if you complete the 
survey.  
 
4. Select which option meets your individual preference. 
 
As an additional thank you, I have created a “helpful links” page that you can access 







Thank you for your time. Your participation is important for continued prevention efforts of 





Emily McCave, MSW    Marianne Berry, Ph.D. 
Doctoral Candidate    Faculty Supervisor    
Department of Social Welfare              Department of Social Welfare 
Twente Hall                          Twente Hall 
University of Kansas     University of Kansas                            
Lawrence, KS 66045                 Lawrence, KS 66045                               
(785) 864-3824                                    (785) 864-2378 









































We support the study conducted by Emily McCave regarding HPV vaccination 
actions, barriers, and supports with girls ages 9-17. Your participation will provide 
valuable insight into the factors that influence clinician’s decisions to administer the 
HPV vaccine.  For each questionnaire returned, $1 will be donated by Ms. McCave to 
the American Cancer Society, an organization that is nationally recognized for its 
efforts to eliminate cancer.  
 
Our interest in HPV Disease and the vaccine developed due to the high prevalence in 
the college-age population.  
 





Kathy Guth, ARNP                             Carolyn N. Johnson, MD 
Gynecologic Nurse Practitioner          Obstetrician and Gynecologist 
                                          




















Approved by the Human Subjects Committee Lawrence Campus, University of Kansas.  
Approval expires one year from 12/4/2007.  
 
 Dear Clinician, 
Recently you received a letter inviting you to participant in my dissertation study about the 
HPV vaccine that may be of interest to you. I hope you will take a moment to review the 
information statement below, which describes this study and how you can be a part of it. I 
have enclosed a paper copy of the brief survey and would be most grateful if you would 




The School of Social Welfare at the University of Kansas supports the practice of 
protection for human subjects participating in research. The following information is 
provided for you to decide whether you wish to participate in the present study. You should 
be aware that even if you agree to participate, you are free to withdraw at any time without 
penalty. 
  As a doctoral candidate at the University of Kansas, School of Social Welfare, I am 
conducting this dissertation study to better understand the behaviors of clinicians treating 
girls aged 9-17 in regards to the new HPV vaccine (Gardasil™). I am also interested in 
hearing about your perceived barriers and supports that you may encounter related to 
vaccinating girls aged 9-17. To obtain this information, I am asking for your completion of 
my questionnaire, which is expected to take approximately 10 minutes to complete.  
   The content of the questionnaires should cause no more discomfort than you would 
experience in your everyday life. Participation may benefit you directly, as you have been 
provided an informational handout on HPV vaccine and state related information. 
Additionally, for every survey completed, I will donate $1 to the American Cancer Society. 
There is the potential for $1500 to be donated to this nationally recognized organization.  
Your participation is solicited, although strictly voluntary. Your name will not be 
associated in any way with the research findings. A unique identifier is placed on your return 
envelope only to assist in tracking non-respondents. Your returned survey, which does not 
have the unique identifier, will be separated from your envelope to ensure anonymity. Both 
your returned survey and envelope will be kept in separate locked cabinets.  
Completion of the survey indicates your willingness to participate in this project and 
that you are at least age eighteen. Please complete the entire survey and use the stamped 
return envelope provided. You may retain this information statement. If you have any 
additional questions about your rights as a research participant, you may call (785) 864-7429 
or write the Human Subjects Committee Lawrence Campus (HSCL), University of Kansas, 
2385 Irving Hill Road, Lawrence, Kansas   66045-7563, email dhann@ku.edu. If you would 
like a copy of the final study results or you would like additional information concerning this 










Emily McCave, Doctoral Candidate  Marianne Berry, Ph.D. 
Principal Investigator                           Faculty Supervisor    
Department of Social Welfare              Department of Social Welfare 
Twente Hall                          Twente Hall 
University of Kansas     University of Kansas                            
Lawrence, KS 66045                 Lawrence, KS 66045                               
(785) 864-3824                                    (785) 864-2378 






































HPV Vaccine Related Barriers, Supports, and Clinician Actions Questionnaire 
 
This questionnaire is to assess your perceived barriers, supports, and actions as a clinician as it relates 
to HPV vaccination of girls aged 9-12 and 13-17. It will take approximately 5 minutes for you to 
complete the entire questionnaire. Included is a self-addressed, stamped envelope for your survey to be 
returned in within the next 7 to 10 days. As the HPV vaccination is attempting to reduce cervical 
cancer rates, for every completed survey that is returned for this study, $1 will be donated to the 
American Cancer Society (http://www.cancer.org), with the potential for $1500 to be donated to this 
organization. As your time is limited and your responses are very valuable in gathering this important 
information, this survey has been refined to be quick and easy as possible.  
 
Please check the responses that describe your specific practice and demographic characteristics. 
 
1. Type of Clinician:      Nurse Practitioner           
            Physician’s Assistant   
          Family Physician      
          Pediatrician    
          Gynecologist    
          Other ____________     
 
2. Years Practicing as Clinician: _______ 
 
3. State in which you Practice:   New Mexico  County: ______________ 
                                             Texas    County: ______________         
                       Louisiana   County: ______________ 
          North Carolina  County: ______________ 
 
4. Hours a Week of Direct Practice with Girls Aged 9 to 12:  ________  
 
5. Hours a Week of Direct Practice with Girls Aged 13 to 17: ________ 
                    
6.  Percentage of Patients Aged 9-17 who are Minority Patients: _________ %   
(Minority Patients Include Hispanics, African Americans, Native Americans and Native Alaskans, 
Asians, Native Hawaiians and other Pacific Islanders) 
  
7.  Percentage of Patients Aged 9-17 who are Private Insurance Patients:  _________ % 
 
8. Are you or your Employer Registered as an Official Vaccines for Children (VFC) Site?    
Yes     No  
 
9. Is your practice through:   Public Clinic   
      Private Clinic      
      University Clinic  
      Other: _________  
             
10. Gender:   Male         Female       
  





12. Ethnic/Racial Category:  Black or African American    
     Please check all that apply      Native Hawaiian or  
Other Pacific Islander                      
                                                     Latino or Hispanic      
            American Indian or Alaska Native   
               White or Caucasian       
Asian      
              Other: _____________             
 
Please answer the questions below that ask about your HPV vaccination actions. 
 
 13. Patient Information-- HPV Vaccination Percentage 
a What percentage of your female patients aged 9-12 have you vaccinated against HPV? 
 
b What percentage of your female patients aged 13-17 have you vaccinated against HPV? 
 
c 
Of those female patients you have vaccinated, what percentage have 




Of those female patients you have vaccinated, what percentage have 
received the HPV vaccine for free or at a discount through public 













14.  Actions 
Have you done any of these activities with each age 
group? 
 
Girls ages 9-12 Girls ages 13-17 
Yes No Yes No 
a 
Sought out more information about HPV or the 
HPV vaccine 
 
    
b 
Asked a nurse to counsel a parent on the HPV 
vaccine 
 
    
c 
Counseled a parent on the Vaccines for Children 
Program (VFC) 
 
    
d 
Referred individual to a specialist for the HPV 
vaccine 
 
    
e 
Referred to a public health clinician (clinic or 
health dept) 
 
    
f 
Counseled parent on the HPV vaccine (such as 
on safety, efficacy, cost, sexual 
nature/implications) 
    
 In which group does the parent typically initiate conversation regarding the HPV 





15. Have you or your clinic ever requested an increased vaccine supply?    Yes          No    
 
 
16. Have you or your clinic ever kept your HPV vaccine supply low to protect against financial loss?   




17. How much have you or your clinic spent purchasing and storing the HPV vaccine?    
$10,000 or less             
$10,001 – 50,000           
  $50,001 – 100,000                                                                                                                           
$100,001 – 150,000     
$150,001 or more        
 
Below are a number of personal and professional factors that may be connected with vaccination 
decisions made by clinicians, such as barriers and supports. For each statement, please check the 
response that best describes how the statement applies to you.  
These statements concern only your perceptions, not the perceptions of your patients. 
 
18. Have you experienced any of the following 
personal or professional barriers (anything that 
inhibits actions) related to providing the HPV 
vaccine female patients in these age groups?  
 
Personal Barriers 
Girls ages 9-12 Girls ages 13-17 
Yes No Yes No 
a 
Limited personal knowledge or education 
on HPV or HPV vaccine     
    
b 
Personal discomfort with talking with 
parents about the HPV 
vaccine for girls because of its sexual 
nature 
    
c 
Concerns about Merck’s Products or the 
Lobbying by Merck 
for Gardasil™    
    
vaccine? (may be one or both groups) 
 
In which group does the patient typically 
initiate conversation regarding the HPV 
vaccine? (may be one or both groups) 
    
 
In which group does another clinician typically 
initiate conversation regarding the HPV 
vaccine? (may be one or both groups) 
    
 
In which group do you typically initiate 
conversation regarding the HPV vaccine? (may 
be one or both groups) 
    
g Other (please explain)  
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d 
Belief that media is marketing the HPV 
vaccination too much 
 
    
e 
Limited personal knowledge or education 
about the current policy initiatives in your 
state promoting HPV vaccination 
    
Professional Barriers     
f Concerns about the safety of the vaccine (short-term or long-term effects)  
    
g Concerns about the effectiveness of the vaccine   
    
h 
Belief that giving the HPV vaccine is 
outside the scope of your practice or 
medical specialty   
    
i Concerns that HPV vaccine will reduce future Pap Smear screenings 
    
j 
Concerns about the financial burden of the 
HPV vaccine (cost to patient, limited 
insurance coverage, or cost to clinic) 
    
k Concerns about patients’ negative perceptions of the HPV vaccine 
    
l 
Concerns about your state’s  policy 
initiative (or lack of policy initiative) to 
increase HPV vaccination  
    
m 




    
 
        
19. Of all the barriers you have experienced, which two have had the most impact on inhibiting 






20. Have you experienced any of the following 
personal or professional supports (aids to vaccination) 
related to providing the HPV vaccine to female patients 
in these age groups?  
 
Personal Supports  
Girls ages 9-12 Girls ages 13-17 
Yes No Yes No 
a 
Personal comfort level talking with parents 
of girls about the HPV vaccine and the 
sexual nature of HPV  
    
b Having a positive personal experience related to the HPV vaccine (such as having a 
    
 140
daughter vaccinated)  
c 
Personal attitude/belief that administering the 
HPV vaccine will have a positive impact on 
young women’s lives  
    
d Exposure from the media about the HPV vaccine 
    
Professional Supports     
e 
Extra information provided within 
employment site about HPV or the HPV 
Vaccine      
    
f 
Presentation from a social worker or medical 
professional about how to talk with parents 
about the vaccine 
    
g 
Presentation from a social worker or medical 
professional about the options for financial 
assistance for the vaccine   
    
h 
Having the opportunity to provide the 
vaccine free or at reduced cost to those who 
do not qualify for Medicaid or low-income 
assistance 
    
i 
Having either an internal or external forum to 
talk with other clinicians about the HPV 
vaccine   
    
j 
Professional adherence to the Advisory 
Council on Immunization Practices (ACIP) 
recommendations for HPV vaccination of 
female patients 
    
k Your state’s policy initiative aimed at promoting HPV vaccination 
    
l 
Other (Personal or Professional): Please 
explain 
 
    
 
 
21. Of all the supports you have received, which two have had the most impact on promoting your 
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Hello! I am a doctoral candidate at the University of Kansas, School of Social Welfare. I am 
interested in understanding your perceptions and behaviors with the new HPV vaccine, 
particularly around vaccination of girls between the ages of 9 and 17. You have been selected 
to participate in this study, which involves taking a short survey.  You will find a letter of 
support on the backside of this page from clinicians like yourself who are familiar with my 
study. For your convenience there is a stamped envelope for you to return your completed 
survey. Important information about the benefits of the study and consent information is 




The School of Social Welfare at the University of Kansas supports the practice of 
protection for human subjects participating in research. The following information is 
provided for you to decide whether you wish to participate in the present study. You should 
be aware that even if you agree to participate, you are free to withdraw at any time without 
penalty. 
  As a doctoral candidate at the University of Kansas, School of Social Welfare, I am 
conducting this dissertation study to better understand the behaviors of clinicians treating 
girls aged 9-17 in regards to the new HPV vaccine (Gardasil™). I am also interested in 
hearing about your perceived barriers and supports that you may encounter related to 
vaccinating girls aged 9-17. To obtain this information, I am asking for your completion of 
my questionnaire, which is expected to take approximately 10 minutes to complete.  
   The content of the questionnaires should cause no more discomfort than you would 
experience in your everyday life. For every survey completed, I will donate $1 to the 
American Cancer Society. There is the potential for $1500 to be donated to this nationally 
recognized organization. There is also relevant HPV information at my google page, which is 
listed below. 
Your participation is solicited, although strictly voluntary. Your name will not be 
associated in any way with the research findings. A unique identifier is placed on your return 
envelope only to assist in tracking non-respondents. Your returned survey, which does not 
have the unique identifier, will be separated from your envelope to ensure anonymity. Both 
your returned survey and envelope will be kept in separate locked cabinets.  
Completion of the survey indicates your willingness to participate in this project and 
that you are at least age eighteen. Please complete the entire survey and use the stamped 
return envelope provided. You may retain this information statement. If you have any 
additional questions about your rights as a research participant, you may call (785) 864-7429 
or write the Human Subjects Committee Lawrence Campus (HSCL), University of Kansas, 
2385 Irving Hill Road, Lawrence, Kansas   66045-7563, email dhann@ku.edu. If you would 
like a copy of the final study results or you would like additional information concerning this 






Emily McCave, MSW    Marianne Berry, Ph.D. 
Doctoral Candidate    Faculty Supervisor    
Department of Social Welfare              Department of Social Welfare 
Twente Hall                          Twente Hall 
University of Kansas     University of Kansas                            
Lawrence, KS 66045                 Lawrence, KS 66045                               
(785) 864-3824                                    (785) 864-2378 
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